Analysis of porcine cytokine response upon *Streptococcus suis* infection

in vivo, in whole blood and in cell culture

Von der Fakultät für Lebenswissenschaften

der Universität Leipzig

genehmigte

D I S S E R T A T I O N

zur Erlangung des akademischen Grades

Doctor rerum naturalium

Dr. rer. nat.

vorgelegt

von

Master of Science Florian Hohnstein

geboren am 04.01.1991 in Leipzig

Dekan: Prof. Dr. Marc Schönwiesner

Gutachter: Prof. Dr. Thomas Magin

Prof. Dr. Peter Valentin-Weigand

Tag der Verteidigung: 07. Januar 2022
Meinen Eltern und Großeltern
Die vorliegende Dissertationsschrift wurde von Herrn Prof. Dr. rer. nat. Thomas Magin betreut und am Institut für Immunologie der Veterinärmedizinischen Fakultät der Universität Leipzig unter der Leitung von Herrn Prof. Dr. med. vet. Gottfried Alber angefertigt.

Teile der vorliegenden Arbeit wurden publiziert (von MDPI lizenziert unter CC BY 4.0; https://creativecommons.org/licenses/by/4.0/; Änderungen wurden vorgenommen):

# INHALT

Inhalt .............................................................................................................................................. I

Bibliographische Darstellung .................................................................................................. III

Abbreviations ........................................................................................................................... IV

1. Introduction .......................................................................................................................... 1
   1.1. *Streptococcus suis* .......................................................................................................... 1
   1.2. Pathogenesis of *S. suis* infection in pigs ......................................................................... 3
      1.2.1. The immunological gap .............................................................................................. 3
      1.2.2. From colonization to invasion ...................................................................................... 4
      1.2.3. Immune responses and immune evasion in invasive *S. suis* infection ...................... 5
      1.2.4. Cytokines and septicemia .......................................................................................... 6
   1.3. Aim of the study ................................................................................................................ 7

2. Material and Methods ........................................................................................................... 8
   2.1. Material and Animals ....................................................................................................... 8
      2.1.1. Bacterial strains .......................................................................................................... 8
      2.1.2. Blood and serum donors ............................................................................................. 8
      2.1.3. Chemicals .................................................................................................................... 8
      2.1.4. Consumables ................................................................................................................ 9
      2.1.5. Devices and software .................................................................................................. 10
   2.2. Methods ............................................................................................................................. 12
      2.2.1. Growth and preparation of bacterial strains ................................................................. 12
      2.2.2. Animal experiments and blood sampling .................................................................... 13
      2.2.3. Isolation of PBMC and granulocytes by density gradient centrifugation .................. 14
      2.2.4. Separation of monocytes by magnetic cell sorting (MACS) ...................................... 15
      2.2.5. Cell counting ............................................................................................................... 16
      2.2.6. Cell culture and stimulations ...................................................................................... 16
      2.2.7. Flow cytometry .......................................................................................................... 17
      2.2.8. Bactericidal assay ....................................................................................................... 17
ABBREVIATIONS

°C Degree Celsius
ABTS 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)
BMDC Bone marrow-derived dendritic cell
BSA Bovine serum albumin
CD Cluster of differentiation
CDS Colostrum-deprived serum
cfu Colony-forming unit
cps Capsular polysaccharide
DC Dendritic cell
EC Endothelial cell
EDTA Ethylenediaminetetraacetic acid
EF Extracellular factor
ELISA Enzyme-linked immunosorbent assay
FBS Fetal bovine serum
FCM Flow cytometric measurement
x g Gravity
H₃PO₄ Phosphoric acid
IFN Interferon
IMDM Iscove's Modified Dulbecco's Medium
Ig Immunoglobulin
IL Interleukin
i.v. intravenous
LPS Lipopolysaccharide
LTA Lipoteichoic acid
MACS Magnetic cell sorting
MLST Multilocus sequence typing
MRP Muramidase-released protein
MRSA Methicillin-resistant *Staphylococcus aureus*
NET Neutrophil extracellular trap
OD Optical density
PAMP Pattern-associated molecular pattern
PBMC Peripheral blood mononuclear cell
PBS Phosphate-buffered saline
PCR Polymerase chain reaction
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>PMA</td>
<td>Phorbol-12-myristat-13-acetat</td>
</tr>
<tr>
<td>PRR</td>
<td>Pattern recognition receptor</td>
</tr>
<tr>
<td>RT</td>
<td>Room temperature</td>
</tr>
<tr>
<td>SLY</td>
<td>Suilysin</td>
</tr>
<tr>
<td>SNP</td>
<td>Single nucleotide polymorphism</td>
</tr>
<tr>
<td>STSS</td>
<td>Streptococcal toxic shock syndrome</td>
</tr>
<tr>
<td>Th</td>
<td>T helper cell</td>
</tr>
<tr>
<td>TLR</td>
<td>Toll-like receptor</td>
</tr>
<tr>
<td>TMB</td>
<td>Tetramethylbenzidine</td>
</tr>
<tr>
<td>TNF</td>
<td>Tumor necrosis factor</td>
</tr>
<tr>
<td>WT</td>
<td>Wild type</td>
</tr>
</tbody>
</table>
1. INTRODUCTION

Streptococci are one of the most prominent groups of bacteria and can be found as commensals and pathogens across many vertebrate hosts, including humans. Until the beginning of the 20th century scarlet fever was one of the most problematic streptococcal infections for western societies. Even today, only four streptococcal species are responsible for a range of common human diseases: Streptococcus (S.) pyogenes (Lancefield group A streptococcus; e.g. pharyngitis, toxic shock syndrome, acute rheumatic fever), S. agalactiae (Lancefield group B streptococcus; e.g. sepsis in newborns), S. pneumoniae ("pneumococcus"; e.g. pneumonia, otitis media, meningitis, bacteremia), and S. mutans (e.g. dental caries) (1). Additional streptococcal species are common pathogens in domestic animals, including horses (S. equi, S. zooepidemicus, S. pneumoniae), cattle (S. uberis, S. agalactiae, S. dysgalactiae, S. zooepidemicus), dogs (S. canis), and pigs (S. suis, S. porcinus), some of which also have zoonotic potential (2). Since S. suis is being found in almost 100% of pig farms worldwide (3) and common serotypes in pig breeding have even been isolated from wild boars (4), S. suis is one of the most prevalent pathogens in pigs.

Since pigs are important for nutrition of many societies globally, S. suis outbreaks do not only happen frequently in pig herds, but occur also in humans, mostly causing meningitis (5, 3) and in some cases even Streptococcal toxic shock syndrome (STSS) (6). Most cases in humans occur in abattoir workers or people who are frequently exposed to raw meat (5, 7, 8). However, S. suis is among the leading causes of meningitis in Vietnam, Thailand and Hong-Kong (9–12) and infected 215 people in an epidemic outbreak among farmers in Sichuan Province, China, in 2005 with a mortality rate of 20%, and S. suis is consequently being recognized as an emerging zoonotic agent (13, 14).

The economic importance of pig breeding coupled with the epidemic potential in humans could be the reason for the increased research interest in S. suis, which is reflected by growing numbers of S. suis-related publications (13). Extensive research on the molecular characteristics and pathogen-host interactions of S. suis has been done using porcine, rodent and human models. However, the knowledge of the pathogenesis of S. suis-related disease is still limited and a cross-protective vaccine for pigs against multiple serotypes is still missing in Europe. Current research aims to expand the understanding of the pathogen and the development of a vaccine by combining expertise from both the human and the porcine background, which should ultimately benefit human and veterinary medicine alike.

1.1. Streptococcus suis

Streptococcus suis is a gram-positive, encapsulated coccus. S. suis expresses several molecular factors which are believed to be linked to virulence, some of the most investigated being suilysin.
(SLY), muramidase-released protein (MRP), extracellular factor (EF), and the bacterial capsular polysaccharide (cps), the latter being used to discriminate between serotypes of \textit{S. suis}.

\textbf{Identification of \textit{S. suis} serotypes}

For diagnostic purposes, \textit{S. suis} is cultivated on sheep blood agar plates where it typically forms gray-white colonies and shows \(\alpha\)-hemolysis (incomplete hemolysis, i.e. oxidization of hemoglobin by hydrogen peroxide produced by the bacteria).

Serological characterization is based on the presence of different epitopes on the surface of the bacterial capsule. These epitopes can be detected by antibodies from antisera raised against reference strains. All currently established serological tests are based on the immunoreactivity of the reference sera with the capsular epitopes. The most common method is the co-agglutination test \((15, 16)\); an inconclusive co-agglutination test can be followed by capillary precipitation or Neufeld’s capsular reaction \((17)\). Depending on the outcome of the test, the isolate can be assigned to one of several described serotypes. This classification is constantly being revised and updated based on the latest insights form biochemical and molecular genetic analyses of serotypes, and has currently reached a consensus of over 30 distinct serotypes \((18–26)\), the most common in Europe being serotypes 7, 9 and 2 \((3)\).

The structure and content of the bacterial capsule is genetically encoded in the \textit{capsular polysaccharide biosynthesis (cps)} locus, a cluster of genes coding for a number of proteins required for transcriptional regulation and several steps in the biosynthesis of the capsule, including a capsular polysaccharide polymerase \((27)\). Most differences between serotypes at this \textit{cps} locus can be detected by polymerase chain reaction (PCR) \((28, 29)\). A commonly accepted nomenclature defines a serotype by the corresponding \textit{cps} locus detected via PCR. Accordingly, serotypes 2, 9 and 7 will be referred to as \textit{cps2}, \textit{cps9} and \textit{cps7} throughout this manuscript.

Since the capsules of some serotypes seem to share surface epitopes and other serotypes share \textit{cps} genes, neither serology \((19, 30)\) nor genotyping by PCR \((31)\) alone can accurately differentiate between some of the currently described serotypes. Multilocus sequence typing (MLST) allows for a more detailed and at the same time very robust analysis of \textit{S. suis} isolates, because it allows for the comparison of differences between isolates at conserved genetic loci, like housekeeping genes. A now widely-used MLST model on the basis of seven \textit{S. suis} housekeeping genes was introduced in 2002 by King \textit{et al.} \((32)\).

In a more recent approach, identification of serotypes is further complemented by analysis of the presence or absence of prominent virulence factors (e.g. SLY, MRP, EF) as an addition to PCR or MLST \((33–35)\).
1.2. **Pathogenesis of S. suis infection in pigs**

Similar to other porcine pathogens, such as *Staphylococcus aureus* (36), *Haemophilus parasuis* (37), *Streptococcus dysgalactiae* and several species of *Lactobacillus* (38), *S. suis* usually colonizes the mucosa of the upper respiratory tract, the urogenital tract and secondary lymphatic organs like lymph nodes and tonsils asymptomatically and is therefore considered a commensal (39–44). Already shortly after birth bacteria can be found in the saliva (45) and in secondary lymphatic organs like palatine and nasopharyngeal tonsils or mandibular lymph nodes of piglets (39, 42, 46, 47). Newborn piglets are usually infected because of high bacterial load in the vaginal tract (43), nasal or vaginal secretions, feces or milk (47) of the mother. While piglets carry different serotypes and strains of *S. suis* on their mucosa, only infections from a few virulent strains will cause disease (43, 48). Serotypes 1-9 are most prevalent in bacterial isolates from diseased pigs (49–52) and most serotypes are commonly found in the brain, joints and the lung (53). Transmission of these strains in breeding facilities may happen through vertical or horizontal transmission by direct contact or aerosol (43, 46, 54), by environmental contamination, like feed troughs (55), fomites like veterinary or farm equipment (55, 56), or even vectors like flies (57). Spread among piglets seems to be associated with excessive changes in environmental temperature, high relative air humidity, crowding, and groups of piglets with a difference in age of more than 2 weeks (58). A different tendency among serotypes to form aerosols has been reported as well (59).

When invasion of the blood by bacteria (i.e. bacteremia) is not controlled early by the immune system, it usually results in systemic inflammation which produces symptoms like fever, fatigue, loss of appetite and, in the case of a septic or toxic shock, low blood pressure. On a cellular level, the transition from bacteremia to septicemia is accompanied by a rapid first response of innate immune cells and subsequent cytokine release, which can trigger further cytokine release, recruitment of other innate and adaptive immune cells, and ultimately responses by T and B lymphocytes. Uncontrolled release of pro-inflammatory cytokines, a so-called cytokine storm, can result in multiple organ failure and death (60). The causes for cytokine storms are complex and not well understood.

1.2.1. **The immunological gap**

Suckling piglets are passively protected by immune cells as well as IgG antibodies received with the colostrum from the mother sow (61). Pigs start producing own antibodies only after weaning when maternal antibody levels have decreased, which results in a state of temporary deficiency in protective antibodies, also called the „immunological gap“ (Figure 1). During this period piglets are especially prone to outbreaks of various diseases, such as meningitis, endocarditis, arthritis or septicemia, which can result in losses of up to 14 % of a pig herd (39, 62, 63). The development
of a serotype-independent *S. suis* vaccine to be applied early in life of piglets would help young pigs to mount a strong protective immune response against virulent *S. suis* right before or after weaning and prevent invasive infection.

![Diagram](image)

**Figure 1** - Outline of the immunological gap in weaning piglets. The innate immune system develops in the embryonic stages. After birth, the piglet is passively protected by maternal antibodies which are taken up with the colostrum. During this period the piglet's own adaptive immunity starts to develop. After weaning at around 6 weeks of age, it takes another few weeks until the adaptive immune system is fully developed, which leaves the animal with an insufficient humoral protection. This period is called the „immunological gap”. Modified after Butler et al., 2007 (64), Axis not proportional.

During the weaning period, piglets undergo changes in the colonizing bacterial flora of the mucosa, especially of the tonsils and nasopharynx (38, 42). The porcine tonsils are considered to be one of the main portals of entry for *S. suis* resulting in systemic spread through blood or the lymphatic system (46, 65, 66). Accordingly, epidemic strains can survive in the tonsils for prolonged periods of time (67).

The mechanisms behind the transition from colonization to invasion are still poorly understood. Since dissemination of *S. suis* in pigs occasionally results in septicemia and death (68, 65), it is crucial to better understand the mechanisms and processes underlying colonization and invasion. However, the cellular, molecular or environmental factors required for the transition of colonization to invasion is still largely unclear.

1.2.2. **From colonization to invasion**

It is currently assumed that *S. suis* can cross the mucosa of the respiratory tract to become invasive (68). Tissue damage by induction of pro-inflammatory mediators at the epithelial barrier could be one mechanism for spread of invasive *S. suis* strains from mucosal surfaces. Dang et al. found that *S. suis* upregulates pro-inflammatory mediators like TNF, IL-6 and IL-8 on a transcriptional level when swine tracheal epithelial cells are co-infected with swine influenza virus (69). In a more mechanistical approach, Wang et al. then showed that swine tracheal epithelial cells are more prone to bacterial adhesion and invasion when pre-infected with swine influenza virus and also
induces TNF, IL-6 and IL-8 (70). This supports the theory that inflammation and tissue damage (each might be induced by co-infection) may promote the spread of *S. suis* systemically.

The most popular theory to explain the spread of *S. suis* to peripheral organs has been the “trojan horse theory”, which states that bacteria are internalized, but not killed by monocytes, and can thereby pass the blood-brain barrier to cause meningitis (71). However, it is currently assumed that bacteria travel through the bloodstream extracellularly, avoiding phagocytosis through their bacterial capsule and possibly attaching to blood monocytes externally (“modified trojan horse theory”) (68, 72, 73).

### 1.2.3. Immune responses and immune evasion in invasive *S. suis* infection

Since the innate immune system is the first line of defense against *S. suis*, it is crucial to understand the interactions of its bacterial components with immune cells. Virulence factors are diverse and it is still unclear which virulence factors exactly play an essential role in the pathogenesis of *S. suis*-associated disease, especially since virulence of *S. suis* seems to depend on the individual set of expressed virulence factors, which can vary greatly even between strains of the same serotype (74). However, especially structural components of the bacterial cell wall and capsule have been shown to be effectively sensed by cells of the innate and adaptive immune system.

The most effective mechanisms of killing of *S. suis* rely on an interplay of innate and adaptive immune responses, namely by antibody-mediated opsonization, (opsono-)phagocytosis by neutrophils and activation of the complement system (75). This is best illustrated by the immune evasion mechanisms of *S. suis*: It has been shown that *S. suis* can induce the formation of neutrophil extracellular traps (NETs) and evade trapping (76). Complement killing and opsonization can be impaired through expression of an immunoglobulin M-degrading enzyme which can degrade specific IgM (77, 78). The virulence factor suilysin is toxic to neutrophils and reduces opsonization and thereby complement-dependent killing of *S. suis*. These immune evasive properties as well as a decreased activation of pro-inflammatory mediators may be mediated by sialic acid (79, 80). The capsular polysaccharide (cps) is a heavily investigated virulence factor of *S. suis* with anti-phagocytic properties, which has been shown to play important roles in protection against killing by neutrophils and dendritic cells (DC) (27, 81–86), but is poorly immunogenic since it only induces low amounts of cps-specific antibodies (87). A study in human monocyte-derived dendritic cells showed that *S. suis* cps2 was able to resist intracellular killing by DCs and modulate cytokine production towards a more anti-inflammatory profile compared to other serotypes (88). Furthermore, the bacterial capsule of a serotype 2 strain has been shown to play a partial role in impairing MHC-II-restricted antigen presentation of dendritic cells, and *S. suis* reduced production of IL-12p40, IL-2 and TNF-α, which are cytokines associated with a T helper
cell 1 (Th1) response (89). This is in line with another study in mouse splenocytes, which also showed that the cps limited the release of Th1-derived cytokines like TNF-α or IFN-γ (90).

1.2.4. Cytokines and septicemia

It has long been known that septicemia and more severe outcomes like sepsis in humans are generally associated with monocytes and macrophages producing exuberant levels of pro-inflammatory cytokines, such as IL-6, TNF-α, IL-1β, or IL-8 (91–93). In LPS-mediated septic shock, activation of monocytes and macrophages even leads to an increase of anti-inflammatory IL-10, which, however, is not able to control the increase in pro-inflammatory cytokines (94).

So far, studies on cytokine induction or sepsis after S. suis infection have mostly been done with whole blood and cell culture models from humans and mice. Studies investigating porcine blood are scarce and have mostly been done in vitro or in culture of peripheral blood mononuclear cells (PBMC).

Human macrophages and murine DCs can detect S. suis through TLR-2 and CD14 (95, 96), but S. suis can also trigger cytokine release by TLR-2- and MyD88-independent pathways (97). It was shown that cell wall components of S. suis stimulate porcine dendritic cells and induce IL-1β, IL-6, TNF-α, IL-12p40, and IL-8 (98). Also, the encapsulated wildtype strain was resistant to phagocytosis, but increases the expression of TLR-2 and -6. Taken together, this supports the notion of a two-sided character of the bacterial capsule, which is able to protect the bacteria against phagocytosis, but at the same time is effectively sensed by pattern recognition receptors (PRR) of the innate immune system.

Graveline et al. showed that S. suis capsule and cell wall can induce TNF-α, IL-6 and IL-1β in mouse macrophages in TLR-2-dependent and -independent ways (95). Segura and colleagues showed that S. suis can potently induce pro-inflammatory cytokines like IL-6, TNF-α, or IL-1β, first in murine macrophages (99), then in a human monocyte cell line (100), and finally in the first in vitro model for porcine whole blood (101). Later it was demonstrated for porcine DCs in vitro that S. suis not only impairs phagocytosis through its cps, but also induces classical pro-inflammatory cytokines, like IL-1β, IL-6, IL-8, IL-12p40 and TNF-α, mostly through cell wall components, and even reduces the expression of the costimulatory molecules CD80/86 and the antigen-presenting MHC-II complex, both of which are crucial for the activation of T cell immune responses (98). A co-infection study with PRRSV showed that IL-6 and TNF-α are synergistically upregulated in bone marrow-derived DCs (BMDC) when additionally infected with S. suis (102).

Prior to our study in vivo data on the relationship between bacteremia, the induced cytokines and their cellular sources in pigs were still missing.
1.3. **Aim of the study**

The aim of this work was to analyze the cytokine response to *S. suis* infection in the blood compartment to understand how bacteremia in piglets is linked with the release of pro- and anti-inflammatory cytokines. Another aim was to compare the *in vivo* situation of bacteremia with *in vitro* models, and to investigate the potential effects of cytokines on bacterial killing. Specifically, the serum levels of TNF-α, IL-6, IFN-, IL-17A, and IL-10 in pigs intravenously infected with *S. suis* were analyzed. Based on *in vivo* data, the cytokine production in whole blood and PBMC was analyzed, and cellular sources of the induced cytokines were evaluated. Furthermore, by concurrent analysis of *S. suis* survival, as well as TNF-α neutralization or addition of recombinant TNF-α, the potential effects of cytokine release on bacterial killing in blood were investigated.
2. MATERIAL AND METHODS

2.1. Material and Animals

2.1.1. Bacterial strains
The cps2 strain 10 (103) and the isogenic capsule mutant strain 10cpsΔEF (27) were kindly provided by Hilde Smith (Wageningen, GE, The Netherlands). The cps7 strain 13-00283-02 and the cps9 strain 16085/3b have been characterized previously in whole-blood killing assays and confirmed to be virulent in experimental infections with piglets (104, 105).

2.1.2. Blood and serum donors
Weaning piglets as blood donors were 7 to 12-week-old German Landrace pigs conventionally bred and held at Lehr- und Versuchsgut Oberholz, Großpösna, Germany or purchased from BHZP GmbH, Dahlenburg-Ellringen, Germany. Piglets in the in vivo infection experiment were bred at Lehr- und Forschungsgut Ruthe, Ruthe/Sarstedt, Germany.

2.1.3. Chemicals
Unless stated otherwise, common laboratory chemicals were purchased from ROTH (Karlsruhe, Germany), Sigma-Aldrich (Taufkirchen, Germany), or Applichem (Darmstadt, Deutschland).

Table 1 - List of used commercial chemicals with manufacturers.

<table>
<thead>
<tr>
<th>Chemical</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diff Quik®</td>
<td>Medion Diagnostics AG, Düdingen, FR, Switzerland</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>Merck KGaA, Darmstadt, Germany</td>
</tr>
<tr>
<td>Gelatine</td>
<td>Carl Roth GmbH + Co. KG, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Glycerol</td>
<td>Carl Roth GmbH + Co. KG, Karlsruhe, Germany</td>
</tr>
<tr>
<td>KPL TMB Microwell Peroxidase</td>
<td>KPL, Gaithersburg, USA</td>
</tr>
<tr>
<td>Penicillin</td>
<td>Merck KGaA, Darmstadt, Germany</td>
</tr>
<tr>
<td>Streptomycin</td>
<td>Merck KGaA, Darmstadt, Germany</td>
</tr>
<tr>
<td>Trypan Blue</td>
<td>Sigma Aldrich, Munich, Germany</td>
</tr>
<tr>
<td>Türk's solution</td>
<td>Merck KGaA, Darmstadt, Germany</td>
</tr>
</tbody>
</table>
### 2.1.4. Consumables

Table 2 – List of used consumables with manufacturers.

<table>
<thead>
<tr>
<th>Consumable</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>96 well micro plates, flat-bottom</td>
<td>Techno Plastic Products, Trasadingen, Switzerland</td>
</tr>
<tr>
<td>96 well micro plates, U-bottom</td>
<td>Techno Plastic Products, Trasadingen, Switzerland</td>
</tr>
<tr>
<td>96 well micro plates, V-bottom</td>
<td>Laborfachhandel Dr. Ilona Schubert, Leipzig, Germany</td>
</tr>
<tr>
<td>Biocoll (1.077 g/ml)</td>
<td>Merck KGaA, Darmstadt, Germany</td>
</tr>
<tr>
<td>Conical centrifuge tubes (50 ml, 15 ml)</td>
<td>Fisher Scientific GmbH, Schwerte, Germany</td>
</tr>
<tr>
<td>Cryo tubes with external thread (1.2 ml)</td>
<td>Techno Plastic Products, Trasadingen, Switzerland</td>
</tr>
<tr>
<td>Dennison Avery adhesive covers</td>
<td>Laborfachhandel Dr. Ilona Schubert, Leipzig, Germany</td>
</tr>
<tr>
<td>Disposable pipette tips (10 µl, 250 µl)</td>
<td>Rainin, Gießen, Germany</td>
</tr>
<tr>
<td>Disposable pipette tips (200 µl, 1,000 µl)</td>
<td>Laborfachhandel Dr. Ilona Schubert, Leipzig, Germany</td>
</tr>
<tr>
<td>Disposable syringes with Luer-Lok™ tips (1 ml, 50 ml)</td>
<td>BD Biosciences, Heidelberg, Germany</td>
</tr>
<tr>
<td>Falcon™ polystyrene round-bottom tubes (5 ml)</td>
<td>Fisher Scientific GmbH, Schwerte, Germany</td>
</tr>
<tr>
<td>Fetal bovine serum Good Forte (batch P161107)</td>
<td>PAN-Biotech GmbH, Aidenbach, BY, Germany</td>
</tr>
<tr>
<td>Iscove’s Modified Dulbecco’s Medium</td>
<td>PAN-Biotech GmbH, Aidenbach, BY, Germany</td>
</tr>
<tr>
<td>MaxiSorp™ round-bottom micro plates</td>
<td>Fisher Scientific GmbH, Schwerte, Germany</td>
</tr>
<tr>
<td>Monovette® Luer for serum (#02.263, 9 ml)</td>
<td>Sarstedt AG&amp;Co, Nümbrecht, Germany</td>
</tr>
<tr>
<td>Monovette® Luer with Lithium heparin (#02.265, 9 ml)</td>
<td>Sarstedt AG&amp;Co, Nümbrecht, Germany</td>
</tr>
<tr>
<td>MS columns</td>
<td>Miltenyi Biotech, Bergisch Gladbach, Germany</td>
</tr>
<tr>
<td>Oxoid™ Columbia agar plates with 5% sheep blood</td>
<td>Fisher Scientific GmbH, Schwerte, Germany</td>
</tr>
<tr>
<td>Polysine® slides</td>
<td>Fisher Scientific GmbH, Schwerte, Germany</td>
</tr>
<tr>
<td>Reaction tubes (2 ml, 1.5 ml, 0.5 ml)</td>
<td>Eppendorf, Hamburg, Germany</td>
</tr>
</tbody>
</table>
Material and Methods

| Shandon™ EZ single Cytofunnel™ for Cytospin™ centrifuge | Fisher Scientific GmbH, Schwerte, Germany |
| Sterican® disposable cannulas (25 G x 1”/30G x ½”) | Braun-Melsungen, Melsungen, Germany |
| Sterile inoculation loops (plastic) | Laborfachhandel Dr. Ilona Schubert, Leipzig, Germany |
| Todd-Hewitt broth | BD Biosciences, Heidelberg, Germany |
| Tryptic soy broth without Dextrose | BD Biosciences, Heidelberg, Germany |

2.1.5. **Devices and software**

Table 3 – List of used devices with manufacturers.

<table>
<thead>
<tr>
<th>Model</th>
<th>Function</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Analytical devices</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BioPhotometer 6131</td>
<td>Spectrophotometer</td>
<td>eppendorf AG, Hamburg, Germany</td>
</tr>
<tr>
<td>LSRFortessa™</td>
<td>Flow cytometer</td>
<td>BD Bioscience, Heidelberg, Germany</td>
</tr>
<tr>
<td>Spectra-Max 340PC384</td>
<td>Microplate reader</td>
<td>Molecular Devices, Sunnyvale, USA</td>
</tr>
<tr>
<td>Synergy™ H1</td>
<td>Microplate reader</td>
<td>BioTek Instruments, Inc., Winooski, USA</td>
</tr>
<tr>
<td><strong>Centrifuges and rotators</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5417R, centrifuge</td>
<td>Centrifuge, refrigerated</td>
<td>eppendorf AG, Hamburg, Germany</td>
</tr>
<tr>
<td>GMC-060</td>
<td>Centrifuge</td>
<td>LMS Co., Ltd., Tokyo, Japan</td>
</tr>
<tr>
<td>Heraeus Megafuge 40R</td>
<td>Centrifuge, refrigerated</td>
<td>Fisher Scientific GmbH, Schwerte, Germany</td>
</tr>
<tr>
<td>Heraeus Primo R</td>
<td>Centrifuge, refrigerated</td>
<td>Fisher Scientific GmbH, Schwerte, Germany</td>
</tr>
<tr>
<td>Shandon™ Cytospin™ 4 Cytocentrifuge</td>
<td>Centrifuge, refrigerated</td>
<td>Fisher Scientific GmbH, Schwerte, Germany</td>
</tr>
<tr>
<td>Stuart SB3</td>
<td>Rotator</td>
<td>Cole-Parmer, Staffordshire, United Kingdom</td>
</tr>
<tr>
<td>Stuart SRT6</td>
<td>Roller mixer</td>
<td>Cole-Parmer, Staffordshire, United Kingdom</td>
</tr>
</tbody>
</table>

**Cooling and heating units**
### Material and Methods

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Supplier Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>BE600</td>
<td>Incubator</td>
<td>Memmert GmbH + Co. KG, Schwabach, Germany</td>
</tr>
<tr>
<td>Heraeus Function Line B20</td>
<td>Incubator</td>
<td>Fisher Scientific GmbH, Schwerte, Germany</td>
</tr>
<tr>
<td>Premium NoFrost</td>
<td>Freezer</td>
<td>Liebherr, Bulle, Germany</td>
</tr>
<tr>
<td>Thermo® Cryotechnics STINOL KG103</td>
<td>Fridge/freezer combination</td>
<td>Fisher Scientific GmbH, Schwerte, Germany</td>
</tr>
<tr>
<td>Thermo® Forma® Series II Water Jacketed CO2 Incubator</td>
<td>Incubator</td>
<td>Fisher Scientific GmbH, Schwerte, Germany</td>
</tr>
<tr>
<td>Thermo® Forma™ -86°C ULT Freezer</td>
<td>Deep freezer</td>
<td>Fisher Scientific GmbH, Schwerte, Germany</td>
</tr>
<tr>
<td>Titramax 1000/Inkubator 1000</td>
<td>Incubator, shaker</td>
<td>Heidolph Instruments GmbH &amp; CO. KG, Schwabach, Germany</td>
</tr>
<tr>
<td>UF 755 GG</td>
<td>Deep freezer</td>
<td>B Medical Systems, Hosingen, Luxemburg</td>
</tr>
</tbody>
</table>

#### Pipets

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Supplier Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bel-Art™ Vaccu-Pette</td>
<td>Autoclavable 96-well pipetting device</td>
<td>Fisher Scientific GmbH, Schwerte, Germany</td>
</tr>
<tr>
<td>eLINE® (50 - 1,000 µl)</td>
<td>Electronic pipet</td>
<td>Merck KGaA, Darmstadt, Germany</td>
</tr>
<tr>
<td>Multipette® plus</td>
<td>Multi-step pipet</td>
<td>Eppendorf AG, Hamburg, Germany</td>
</tr>
<tr>
<td>Pipet-Lite™ (100 - 1,000 µl)</td>
<td>Mechanical pipets</td>
<td>Rainin, Gießen, Germany</td>
</tr>
<tr>
<td>Pipet-lite™ (20-300 µl)</td>
<td>Multi-channel pipet</td>
<td>Rainin, Gießen, Germany</td>
</tr>
<tr>
<td>pipetus®</td>
<td>Electronic pipet for serological tips</td>
<td>Hirschmann Laborgeräte GmbH &amp; Co. KG, Eberstadt, Germany</td>
</tr>
<tr>
<td>Research® (0.5 - 10 µl, 10 - 200 µl, 100 - 1,000 µl)</td>
<td>Mechanical pipets</td>
<td>Eppendorf AG, Hamburg, Germany</td>
</tr>
</tbody>
</table>

#### Miscellaneous

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Supplier Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carl Zeiss™ Axiovert™</td>
<td>Microscope, inverted</td>
<td>Fisher Scientific GmbH, Schwerte, Germany</td>
</tr>
<tr>
<td>HeraSafe, Class 2, Type H laminar flow bench</td>
<td>Laminar flow bench</td>
<td>Fisher Scientific GmbH, Schwerte, Germany</td>
</tr>
<tr>
<td>Mini Vortexer</td>
<td>Vortexer</td>
<td>VWR®, Darmstadt, Germany</td>
</tr>
<tr>
<td>Neubauer-improved counting chamber</td>
<td>Counting chamber</td>
<td>Paul Marienfeld GmbH &amp; Co.KG, Lauda Königshofen, Germany</td>
</tr>
</tbody>
</table>

11
Material and Methods

| VarioMACS separator | Magnetic cell sorting device | Miltenyi Biotech, Bergisch Gladbach, Germany |

Table 4 – List of used software with developers.

<table>
<thead>
<tr>
<th>Software</th>
<th>Purpose</th>
<th>Developer</th>
</tr>
</thead>
<tbody>
<tr>
<td>BD FACSDiva™, flow cytometry</td>
<td>Flow cytometry recording software</td>
<td>BD Bioscience, Heidelberg, Germany</td>
</tr>
<tr>
<td>FlowJo, v.10.6.0, flow cytometry</td>
<td>Flow cytometry analysis software</td>
<td>FlowJo LLC, Ashland, USA</td>
</tr>
<tr>
<td>GraphPad PRISM v5.01</td>
<td>Data analysis software</td>
<td>GraphPad Software, Inc., San Diego, USA</td>
</tr>
<tr>
<td>SoftMax Pro, v5.0</td>
<td>Microplate reader software</td>
<td>Molecular Devices, LLC, San Jose, USA</td>
</tr>
</tbody>
</table>

2.2. Methods

2.2.1. Growth and preparation of bacterial strains

- **PBS (pH 7.4):** 137 mM NaCl, 2.7 mM KCl, 1.5 mM KH₂PO₄, 12.9 mM Na₂HPO₄

Bacteria suspensions for stimulation were grown from frozen bacterial stocks stored at – 80 °C in 15% glycerol (v/v in PBS). Frozen bacteria were transferred from the cryo tube to a Columbia agar plate containing 5% sheep blood (Fisher Scientific) using a sterile plastic inoculation loop.

Single colonies were obtained using the fractional smear method: With a clean inoculation loop, the bacterial suspension was spread out in a single, waving line over one fifth of the plate. Then another clean inoculation loop was used to spread part of the first smear over another fifth of the plate, and so on. This gradual thinning is needed to spread the bacterial suspension enough for single colonies to grow on the sheep blood agar. The plated bacteria were incubated over night at 37 °C and 5% CO₂.

On the next day, a single colony was picked with a sterile disposable plastic inoculation loop and resuspended in 5 ml of sterile THB in a 15 ml centrifuge tube. This liquid culture was incubated for 9 hours at 37 °C and 5% CO₂ with a loose screw cap to allow gas exchange between the bacterial culture and the incubator.

Bacterial growth in a liquid culture can be measured indirectly using the optical density (OD) of the culture medium. While light can pass through a clear liquid like water unhindered, a medium containing proliferating bacterial cells will increase in opacity over time and therefore absorb
light increasingly. The optical density can be measured using a spectrophotometer and is expressed as a dimensionless value, with a value close to 0 for clear water and increasing values with higher absorbance of light.

After 9 hours of incubation, the optical density of the liquid bacterial culture was measured at 600 nm (OD\textsubscript{600}). The bacterial suspension was then diluted to an OD\textsubscript{600} of 0.03 in 60 ml of pre-warmed THB in a glass flask and incubated at 37 °C and 5% CO\textsubscript{2} until an OD\textsubscript{600} of 0.6 was reached, which is equivalent to the late exponential growth phase of \textit{S. suis} containing an optimal concentration of viable bacteria.

The resulting bacterial suspension at OD\textsubscript{600}=0.6 was then pelleted by centrifugation at 3,200 x g for 15 min at 4 °C. The supernatant was discarded. Aliquots of bacteria used in whole blood (bactericidal assay) were stored in THB with 15% sterile glycerol (v/v in PBS). Bacteria used for stimulation of PBMC culture were washed twice with sterile PBS (centrifugation at 3,200 x g, 15 min, 4 °C). The washed pellet was resuspended in PBS with 15% sterile glycerol, distributed into 500 µl aliquots and stored at -80 °C.

Since cells were stimulated with thawed aliquots of bacterial suspensions, the bacterial concentration of the aliquots was not determined with fresh bacterial suspensions, but after one freeze-thaw cycle. A frozen aliquot was thawed on ice and diluted up to 1:10\textsuperscript{6} in sterile PBS in a 1:10 dilution series with 6 steps. The dilution was carried out in 200 µl of volume in sterile 96-well micro plates (U-bottom, Techno Plastic Products, Trasadingen, Switzerland). From each dilution 20 µl were plated in duplicates on Columbia agar plates with 5% sheep blood. The droplet was run across the plate by gravity ("running droplet" method). After overnight incubation at 37 °C and 5% CO\textsubscript{2} the average bacterial colony count from each dilution was calculated. The colony count was then calculated back to the bacterial concentration of the stock using a weighted arithmetic mean according to the formula described by Bast (106): 
\[
m = \frac{10^{-x}}{\nu} \sum_{n_x} \frac{c_x + c_{x+1}}{n_x + 0.1 \cdot n_{x+1}},
\]
where \(m\) = weighted arithmetic mean; \(n\) = number of plates; \(10^{-x}\) = dilution factor of the lowest dilution; \(\nu\) = volume used for plating (here 20 µl); \(\Sigma c_x\) = total number of colonies on all plates \((n_x)\) of the lowest dilution \(10^{-x}\); \(\Sigma c_{x+1}\) = total number of colonies on all plates \((n_{x+1})\) of the next higher dilution \(10^{-(x+1)}\).

2.2.2. Animal experiments and blood sampling

All piglets used in this study were from conventional herds with carriers of numerous \textit{S. suis} genotypes. Whole blood samples for \textit{in vitro} experiments were drawn from \textit{Vena cava cranialis} from healthy piglets between 6 and 10 weeks of age (German Landrace, weaned at four weeks of age) in 9 ml lithium-heparin monovettes (Sarstedt AG&Co, Nümbrecht, Germany). Porcine blood was taken in accordance with the permit no. N19/14, approved by the responsible authorities of the state of Saxony, Germany (Landesdirektion Sachsen, Chemnitz, Germany).
**Material and Methods**

*In vivo* data were generated from samples of an independent infection experiment carried out at the University of Veterinary Medicine Hannover, Germany (permit No. 33.8-42502-04-18/2879, Committee on Animal Experiments of the Lower Saxonian State Office for Consumer Protection and Food Safety) with German Landrace piglets from a different herd. The handling and treatment of animals was in strict accordance with the principles of the European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes, as well as the German Animal Protection Law.

Eight-week-old German Landrace piglets (weaned at four to five weeks of age) were intravenously infected under ketamine and azaperone anesthesia with $3 \times 10^8$ cfu of *S. suis* cps2 strain 10 (103). The goal of the infection was to induce meningitis, but no arthritis or shock symptoms. The infection dose was based on experience with previous intranasal and intravenous infection studies in piglets of the same age group with *S. suis* serotype 2 and serotype 9, respectively. PBS was intravenously injected in the control animals under same conditions. Twelve hours post infection, the piglets were anaesthetized through application of ketamine and azaperone, and anesthesia was maintained for six hours (i.e., from 13 to 19 h after intravenous infection) via inhalation of isoflurane while blood was drawn. Blood samples were taken from *Vena jugularis* or *Vena cava cranialis* pre-infection and from *Arteria femoralis*, respectively, at defined time points (0, 13, 16 and 19 h post infection) and filled into serum and plasma (lithium-heparin) monovettes (Sarstedt AG&Co, Nümbrecht, Germany, NW, Germany).

From Li-heparin blood, serial dilutions were plated on Columbia blood agar and the bacterial load (cfu/ml) was determined after incubation at 37°C for 20 h. In addition, serum samples were taken, centrifuged 30 min after blood withdrawal, and immediately frozen after centrifugation in small volumes in liquid nitrogen and stored at -80 °C until usage. Colostrum-deprived serum was obtained from piglets that were born dead without showing signs of decay or from very weak, newborn piglets that were euthanized immediately after birth due to the inability to rise and to take up colostrum.

2.2.3. **Isolation of PBMC and granulocytes by density gradient centrifugation**

- **Erythrocyte lysis buffer**: 0.155 M NH₄Cl, 10 mM KHCO₃, 0.1 mM di-sodium EDTA

PBMC were isolated from whole blood by density gradient centrifugation with Biocoll (1.077 g/ml; Merck KGaA, Darmstadt, Germany). Granulocytes were collected from the pellet of a density gradient separation of whole blood with Biocoll (described above), and again subjected to a second Biocoll density gradient separation. Erythrocytes were removed by incubation in erythrocyte lysis buffer for 5 min on ice.
Control of separation purity of granulocytes by histological staining

To determine the purity of granulocytes, the separated fraction was transferred to glass slides (2 x 10^5 cells/slide) with a Cytospin™ 4 centrifuge at 1,000 rpm centrifugation for 3 min (Fisher Scientific GmbH) and stained with a Diff Quik® staining kit (Medion Diagnostics AG, Düdingen, Switzerland) according to the manufacturer’s instructions with 5 dips in each Diff Quik Fix solution, Diff Quik I solution, and Diff Quik II solution. The frequencies of lymphocytes, monocytes and granulocytes (neutrophils, eosinophils and basophils) out of 100 total cells were determined microscopically with a Carl Zeiss™ Axiovert™ (Fisher Scientific GmbH). The purity of granulocytes determined with this method was 96% (median, Figure 6C). The viability of granulocytes was confirmed by cell count in 0.4% trypan blue solution.

2.2.4. Separation of monocytes by magnetic cell sorting (MACS)

- PBS (pH 7.4): 137 mM NaCl, 2.7 mM KCl, 1.5 mM KH₂PO₄, 12.9 mM Na₂HPO₄
- MACS buffer: 0.5% BSA (v/v), 2 mM EDTA in PBS

Magnetic cell sorting relies on magnetic beads which are coupled to antibodies specific to typical surface markers of cell populations. Monocytes of humans and pigs express the marker CD14 on their surface (107–111) which can be detected with commercially available CD14-specific beads. When the CD14-expressing cells are labelled with the magnetic beads, the cell suspension can be rinsed through a column consisting of magnetized particles. The unlabelled cells are washed out of the column while all cells labelled with the magnetic CD14-beads are retained by the magnetic particles (positive selection). In the next step, the column is demagnetized and the labeled cells with the magnetic CD14-beads can be washed out of the column.

For magnetic cell separation of monocytes, PBMC were labeled with cross-reactive anti-human CD14 microbeads (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) according to the manufacturer’s instructions and separated on MACS® MS columns (Miltenyi Biotec GmbH) in the magnetic field of a VarioMACS separator.

Since antibodies can cross-react with non-specific epitopes, the purification of monocytes had to be validated. The main priority of the experiment was to separate CD14-expressing monocytes and CD3-expressing T cells, which can be distinguished by flow cytometry through fluorescent labelling of characteristic surface markers.

Control of separation purity of the CD14-positive fraction by flow cytometry

To check the purity of the monocyte fraction after separation, the number of monocytes and T cells was determined by flow cytometry in the unseparated PBMCs and in the CD14-positive monocyte fraction. Cells were stained with a viability dye (eFluor™ 506, Fisher Scientific GmbH, Schwerte, Germany), a T cell-specific anti-CD3 antibody (clone BB23-8E6-8C8; Becton Dickinson
GmbH, Heidelberg, Germany), and an antibody against the myeloid marker CD172a ("SWC3", clone 74-22-15A; Becton Dickinson GmbH). Since commercially available antibodies against CD14 for use in flow cytometry did not perform well, this method was chosen to distinguish between T cells and myeloid cells in flow cytometry.

2.2.5. **Cell counting**

To determine cell numbers for cell culture, cell suspensions were diluted with Trypan blue (Sigma Aldrich, Munich, Germany) and given onto a Neubauer counting chamber. Trypan blue accumulates in damaged or dead cells, but is excluded from viable cells. The number of viable cells in a suspension can therefore be determined by counting unstained cells. Viable cells were counted in 4 diagonal small squares across each of the four large corner squares to determine the average number of cells in one large square (16 small squares). Since the depth of the chamber between glass slide and cover slip is 0.1 mm and the area of one large square is 1 mm², the volume above one large square is equal to 0.1 mm³ or 0.1 µl. Therefore, multiplying the cell count of one large square with the factor $10^4$ and with the dilution factor of the cell suspension gives the cell number per ml.

To determine the cell number in whole blood, Türk’s solution (Merck KGaA, Darmstadt, Germany) was used instead of Trypan blue to remove erythrocytes during counting. Türk’s solution contains acetic acid, which results in hemolysis of residual erythrocytes. The gentian violet dye in Türk’s solution stains all leukocytes and allows no evaluation of cell viability.

2.2.6. **Cell culture and stimulations**

**PBMC culture**

Isolated PBMC were seeded into sterile 96-well flat-bottom plates at $10^6$ cells/well in 200 µl Iscove’s Modified Dulbecco’s Medium (IMDM; PAN-Biotech GmbH, Aidenbach, Germany) supplemented with 10% fetal bovine serum (FBS, PAN-Biotech GmbH), 50 µg/ml gentamicin (Merck KGaA), 100 U/ml penicillin, and 100 µg/ml streptomycin (Pen/Strep; Merck KGaA). Viable *S. suis* strains from glycerol stocks were added at PBMC-to-bacteria ratios of 10:1 or 1:1 (corresponding to $10^5$ and $10^6$ cfu/well), as indicated in the respective figure descriptions and legends. After 42 h of stimulation with *S. suis*, supernatants were taken and stored at -20 °C.

**Separation experiments**

For separation experiments, PBMC were cultivated at $10^6$ cells/well (200 µl). CD14-positive monocytes were cultivated at $5 \times 10^4$ cells/well (5% of PBMC); granulocytes were cultivated at $1 \times 10^6$ cells/well. For stimulation, the same final concentration of $10^6$ cfu/well was used for all three fractions (equivalent to a 1:1 ratio of PBMC to bacteria).
**IL-10 neutralization experiments**

For IL-10 neutralization, anti-porcine IL-10 (clone 148801; R&D Systems Inc.) or isotype control mlgG2b (clone 20116; R&D Systems Inc.) were added at 0.1 µg/ml. Bioactivity of clone 148801 has been demonstrated previously (112).

### 2.2.7. Flow cytometry

- **PBS (pH 7.4):** 137 mM NaCl, 2.7 mM KCl, 1.5 mM KH₂PO₄, 12.9 mM Na₂HPO₄
- **Flow cytometry buffer:** 3% FBS (PAN-Biotech GmbH), 0.1% sodium azide (v/v) in PBS
- **Paraformaldehyde (PFA):** 2% (v/v) in flow cytometry buffer

**Staining**

Cells were transferred to 96-well v-bottom microplates (Laborfachhandel Dr. Ilona Schubert, Leipzig, Germany) and washed twice with PBS (380 x g, 3 min, 4 °C). Unless stated otherwise, cells were stained at 4 °C in darkness. After washing, cells were centrifuged at 380 x g for 3 min at 4 °C, the supernatant was discarded and the pellet was resuspended by shaking for 30 s on a microplate shaker/incubator.

To assess cell vitality, cells were stained in 50 µl of an amine-reactive live/dead dye (eFluor™ 506, Fisher Scientific GmbH, Schwerte, Germany) in PBS for 25 min. Amine-reactive dyes penetrate dead or damaged cells and bind to free amines in the cytoplasm. The dye is excluded by live cells and therefore allows a discrimination between viable and dead cells. For staining of surface markers, the cells were washed twice with flow cytometry buffer. Cells were then stained in 40 µl of the corresponding antibody (CD3*PE-Cy7, clone BB23-8E6-8C8; CD172a*FITC, clone 74-22-15A; both from BD Biosciences) for 15 min. For each antibody, a corresponding isotype staining was included to control for unspecific staining. For fixation, cells were washed twice in PBS and then incubated in 2% PFA for 15 min. Cells were finally washed and then resuspended in flow cytometry buffer until flow cytometric measurement.

**Flow cytometric analyses**

Flow cytometric measurements were carried out on an LSR Fortessa™ flow cytometer (BD Biosciences). Flow cytometric data were analyzed with FlowJo software, version 10.6.0 (TreeStar, Ashland, USA).

### 2.2.8. Bactericidal assay

Bactericidal assays were conducted as previously described (78) with some modifications. Briefly, 500 µl of heparinized blood was mixed with *S. suis* strains at a concentration of 2 x 10⁶ cfu/ml (time point t₀) and incubated at 37 °C for 2 or 6 h on a rotator at eight rounds per minute (rpm). To study the time course of TNF-α induction and bacterial survival, whole blood from each piglet was mixed at room temperature with *S. suis* for a final concentration of 2 x 10⁶ cfu/ml. Infected
blood was immediately distributed to separate reaction tubes for each time point (0, 30, 60, 90, and 120 min; 500 µl each) and incubation at 37 °C on a rotator (8 rpm) was started simultaneously for all tubes.

To calculate survival factors, blood was diluted and incubated on Columbia agar in duplicate (running droplet). Colony-forming units (cfu) were counted after overnight incubation at 37 °C. The survival factor at a given time point \( t_x \) was calculated as quotient of cfu at \( t_x \) divided by cfu at \( t_0 \). For functional studies, recombinant porcine TNF-α (10 ng/ml) or neutralizing anti-TNF-α antibody (4 µg/ml; both R&D Systems Inc., Minneapolis, MN, USA) was added. Bioactivity of recombinant TNF-α has been demonstrated previously (113).

For a serum-reconstituted bactericidal assay, whole blood was washed twice with PBS and afterwards supplied with half the initial blood volume of defined sera (e.g., from colostrum-derived pigs).

2.2.9. **Quantification of cytokines by ELISA**

- **PBS (pH 7.4):** 137 mM NaCl, 2.7 mM KCl, 1.5 mM KH₂PO₄, 12.9 mM Na₂HPO₄
- **Washing buffer:** 0.05% Tween®20 (v/v) in PBS
- **Blocking buffer:** 0.1% gelatine (v/v), 0.5% BSA (w/v) in PBS
- **Serum diluent:** 0.1% gelatine (v/v), 0.5% BSA (w/v), 0.05% Tween®20 (v/v) in PBS
- **H₃PO₄ (1M)**

ELISA kits for porcine IL-6, IL-10, and TNF-α were purchased from R&D Systems Inc (Minneapolis, USA). Ninety-six-well plates (Nunc MaxiSorp™ round-bottom; Fisher Scientific) were coated with antibodies according to the manufacturer’s instructions. The biotinylated detection antibodies were coupled with a streptavidin-horseradish peroxidase conjugate (R&D Systems, Inc.) for 20 min at room temperature. The peroxidase was developed with a 3,3′,5,5′-Tetramethylbenzidin (TMB) solution (SeraCare, Milford, MA, USA, formerly KPL) and the reaction was stopped after 20 min with H₃PO₄. Optical density (OD) values were measured with a SpectraMax 340PC384 microplate reader (Molecular Devices, LLC, San Jose, CA, USA) at 450, and at 630 nm as a background reference, and analyzed with SoftMax® Pro v5.0 software (Molecular Devices, LLC).

**Establishment of an ELISA for the quantification of porcine IL-17A**

Since no porcine IL-17A ELISA kits were available commercially, this ELISA was established with a monoclonal anti-porcine IL-17A antibody as coating antibody (clone MT504, Mabtech AB, Nacka Strand, Sweden) and a polyclonal rabbit anti-porcine IL-17A serum for detection (catalog no. KPB0499S, Kingfisher Biotech, Inc., Saint Paul, USA), and a porcine IL-17A standard. Incubation times and reagents were adopted from protocols of commercially available cytokines ELISA kits. A washing step consisted of 3 washes with 250 µl washing buffer each.
Protocol:

Ninety-six-well plates (Nunc MaxiSorp™ round-bottom; Fisher Scientific) were coated with 50 µl of the coating antibody diluted in PBS and incubated over night at RT. On the next day, the plate was washed and incubated with blocking buffer for 1 hour at room temperature to block unspecific binding sites on the plate. After a washing step, the standard was diluted in serum diluent and incubated in 50 µl for 2 hours at RT. The blocking buffer was washed and then 50 µl of the detection antibody diluted in serum diluent was added and incubated for 2 hours at RT. The detection antibody was washed and the detection antibody was coupled to a streptavidin-horseradish peroxidase conjugate (50 µl/well, 1:200 in serum diluent) and incubated for 20 min at RT. After a final washing step, 100 µl of the peroxidase substrate, TMB, was added. After approximately 15 min the reaction was stopped with 50 µl of 1 M H₃PO₄. OD values were detected at 450 (signal) and 630 nm (background).

First, the performance of the coating antibody was evaluated at 5, 2.5, and 1.25 µg/ml with the detection body used at 2.0, 1.0, and 0.5 µg/ml. Porcine IL-17A (MoBiTec GmbH, Göttingen, Germany) was used as a standard in a 1:2 dilution series from 2,000 to 31.25 ng/ml. The standard was detected linearly down to 125 pg/ml with a coating antibody concentration of 5 µg/ml independently of the concentration of the detection antibody (Figure 2). Lower coating antibody concentrations resulted in non-linear OD₄₅₀ measurements.

Finally, the optimal concentration of the detection antibody and the detection limit were determined. The detection antibody was used in a 1:2 dilution series from 0.5 to 0.062 µg/ml; the standard was used in a 1:2 dilution series from 1,000 to 0.6766 ng/ml. A sigmoidal curve was measured at a concentration of 0.5 µg/ml of the detection antibody (Figure 2).
Material and Methods

Figure 2 – Establishment of an ELISA for porcine IL-17A. The performance range of the monoclonal coating antibody (clone MT504, Mabtech AB, Nacka Strand, Sweden) and the polyclonal rabbit anti-pig IL-17A antibody (Kingfisher Biotech, Inc., Saint Paul, USA) using a porcine IL-17A standard (MoBiTec GmbH, Göttingen, Germany). (A) First, the optimal concentration of the coating antibody was tested (5, 2.5, 1.25 µg/ml) using three different concentrations of the detection antibody (2.0, 1.0, 0.5 µg/ml). At a concentration of 5 µg/ml the coating antibody detected the standard at a sufficiently high OD. Concentrations of polIL-17A standard: 2,000, 1,000, 500, 250, 125, 62.5, 31.25 pg/ml. (B) Using the coating antibody at the determined concentration of 5 µg/ml, the detection antibody was tested at lower concentrations (0.5, 0.25, 0.125, 0.062 µg/ml). At 0.5 µg/ml the IL-17A standard was detected optimally. Concentrations of polIL-17A standard: 1,000, 500, 250, 125, 62.5, 31.125, 15.625, 7.8125, 3.9063, 1.9531, 0.9766 pg/ml. The detection limit of the established polIL-17A ELISA is 7.8125 pg/ml (*).

2.2.10. Quantification of S. suis-specific Immunoglobulin (Ig) G by ELISA

- 5% skim milk (v/v): skim milk powder in ddH₂O
- Citrate buffer: 0.003% H₂O₂ (v/v), 500 µg/ml 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)

Round-bottom 96-well plates (Nunc MaxiSorp round-bottom; Fisher Scientific) were coated with S. suis strain 10 and blocked with 5% skim milk solution. After incubation with control and sample sera, S. suis-specific IgG was detected with a polyclonal goat anti-pig IgG antibody (catalog no. A100-105P, Bethyl Laboratories, Inc., Montgomery, USA) coupled to peroxidase. The peroxidase was developed with a citrate buffer containing 0.003% H₂O₂ and 500 µg/ml of the 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) substrate. OD values were measured with a Synergy™ H1 microplate reader (BioTek Instruments, Inc., Winooski, VT, USA) at 450 and at 630
nm as background reference. IgG was quantified in relative units (RU) as a ratio of the samples relative to a control serum, as described previously (66).

2.2.11. **Statistics**

Data analyses were performed with GraphPad Prism v5.01 (GraphPad Software, Inc., La Jolla, CA, USA) to calculate normal distribution. Statistical significance ($\alpha = 0.05$) was calculated with a parametric test for normally distributed data (Student’s t-test) and with non-parametric tests for data that was not normally distributed (Mann-Whitney test, Kruskal-Wallis test and Dunn’s post-hoc test).

### 3. RESULTS

3.1. **Detection of IL-6 and IL-10 in sera of piglets with pronounced bacteremia after intravenous infection with S. suis**

The induction of inflammatory cytokine responses upon streptococcal infection has been demonstrated in previous studies in human whole blood and also by bacterial stimulation in murine *in vitro* models (99, 114, 115). Previously, *S. suis* has been shown to induce pro-inflammatory cytokines in a study with porcine whole blood (101). This study investigated whether *S. suis* induces cytokines during bacteremia *in vivo* after an intravenous infection that mimics bacteremia caused by an invasive infection. Cytokine levels were determined in serum samples taken from nine piglets (weaned at four to five weeks of age; six to ten weeks old at time of analysis) at 0, 13, 16, and 19 h (time points given by the animal permit), six of which were intravenously infected with *S. suis* strain 10 and three of which served as uninfected controls. To prevent stress-induced immunomodulation during blood sampling, all experimental animals were under anesthesia from 13 to 19 h post infection when blood was drawn. Three of six infected individuals developed pronounced bacteremia 13 h post infection (hpi; **Figure 3A**). Two of three pigs with pronounced bacteremia showed an increase in serum IL-6 (**Figure 3B**): individual H7 showed an IL-6 peak of 1.9 ng/ml at 16 hpi, and individual H2 a peak of 0.9 ng/ml at 19 hpi. For IL-10, an increase of serum levels with pronounced bacteremia was also detectable in two of three piglets: piglet H2 showed an increase up to 1.6 ng/ml at 19 hpi. Piglet H3, which did not show elevated IL-6 levels, showed an IL-10 peak of 0.7 ng/ml at 16 hpi. The piglet H7 did not show increased IL-10 secretion. In contrast, no increase in IL-6 or IL-10 levels was detectable in the sera of three pigs, which were able to control bacteremia, as well as in the three uninfected control pigs. In addition, TNF-α, IL-17A and IFN-γ were measured in the serum of all experimental animals, but were not detectable during this time frame.
Results

In summary, it was found that during infection, cytokines are induced *in vivo* in piglets with pronounced *S. suis* serotype 2 bacteremia. However, it remained open whether TNF-α was induced at earlier time points after infection.

![Graph](image)

Figure 3 - Detection of IL-6 and IL-10 post intravenous *S. suis* infection in sera of piglets with pronounced bacteremia. (A) Quantification of bacterial load in blood 0, 13, 16, and 19 h after intravenous infection of six piglets (eight weeks old, weaned at four weeks of age). (B) Cytokine levels in individual sera measured by ELISA before and after infection with *S. suis* strain 10 (cps2, n = 6) and in serum of non-infected control animals (n = 3). Note that earlier time points than 13 hpi could not be taken due to the experimental setup. Some of the bacterial load data shown here were additionally used in another study, though in context with other parameters (116).
3.2. *In vitro* induction of pro- and anti-inflammatory cytokines by *S. suis* is limited by IL-10

As an induction of IL-6 and IL-10 was observed in piglets with pronounced bacteremia, the next step was to test whether cytokine induction could be reproduced in a whole-blood assay upon addition of viable *S. suis*, as has been demonstrated previously (101). Since IL-6 and TNF-α are commonly induced immediately after infection (99, 101), cytokines were measured in plasma at earlier time points (2 and 6 h) after stimulation with *S. suis* than determined in the *in vivo*-infection experiment. To assess the proliferation or killing of *S. suis* in the whole-blood assay, bacterial survival was determined after 2 and 6 h. Whole blood of eight to nine-week-old piglets was stimulated with the same bacterial strain from the infection experiment (strain 10, *cps2*). As a further control, an acapsular mutant of the encapsulated WT strain 10 was used, described as 10cpsΔEF (27), that is known to show an enhanced cytokine release by *S. suis* (101, 95), since the capsule covers the immune-stimulatory cell wall components. Strain 10 induced TNF-α and IL-6 after 2 h and at significantly increased levels after 6 h, while IL-10 was only induced 6 h after stimulation (Figure 4A). The magnitude and time course of the cytokine induction for the acapsular strain was very similar. In contrast to similar cytokine response, the acapsular strain was killed after 2 h, whereas the wild type (WT) strain 10 proliferated within 2 and 6 h after infection (Figure 4B).

In summary, the *in vivo* data could be confirmed in a whole-blood assay (Figure 3) by showing that *S. suis* strain 10 induces pro-inflammatory (i.e., IL-6) and anti-inflammatory (i.e., IL-10) cytokines in blood. In addition, an early TNF-α induction was detected (2 h). Previous findings, that acapsular *S. suis* induces similar cytokine levels, but shows a reduced survival in a porcine whole blood (101), could also be confirmed.
Figure 4 - The induction of pro- and anti-inflammatory cytokines by encapsulated and acapsular *S. suis* strain 10 *in vitro* in whole blood is similar, but bacterial survival is different. (A) Quantification of cytokines in plasma before (0 h, n = 3) and 2 or 6 h after (n = 12) the addition of 2 x 10⁶ colony-forming units (cfu)/ml *S. suis* strain 10 or 10cpsΔEF to whole blood. Median (horizontal line) of all samples are shown; red symbols indicate the individuals that are shown in B. (B) Bacterial survival from the same samples 2 and 6 h after *in vitro* infection. Calculation of survival factors (ts) = (cfu at t₀)/(cfu at tₖ). Bars show median and range of individually calculated survival factors (n = 3). Graphs show data of two independent experiments with eight to nine-week-old piglets. Statistical analysis was conducted by Kruskal–Wallis test and Dunn’s post-hoc test (* p < 0.05, ** p < 0.01, *** p < 0.001).

Bacterial proliferation and/or neutrophil-mediated killing of *S. suis* in the used whole-blood assay can change the ratio of bacteria to blood cells and complicate the interpretation of data. Thus, to exclude bacterial proliferation and to maintain a defined ratio of bacteria to blood cells in the following experiments, isolated PBMC were used in a cell culture system with antibiotics to analyze *S. suis*-induced cytokine production. To prevent phagocytosis and killing as much as possible PBMC were used, which no longer contain granulocytes, since granulocytes are important for bacterial killing (75). PBMC, isolated from healthy weaning piglets, were stimulated with the WT *S. suis* strain 10 and the acapsular mutant. In PBMC the induction of TNF-α, IL-6 and IL-10 by the WT strain was dependent on the bacterial load, but resulted in only marginal cytokine
levels (Figure 5A). In contrast to WT *S. suis*, cytokine induction after stimulation with the acapsular strain was significantly higher, but IL-6 and IL-10 also showed a dose-dependent increase, whereas TNF-α was already strongly induced at a PBMC-to-bacteria ratio of 10:1.

In summary, cytokines were induced by stimulation with the WT strain, dependent on the high bacterial load and on the dose-dependent induction of IL-6 and IL-10 by the acapsular strain. The observed dependency on the bacterial load is in line with the previous findings (Figure 4), since a high bacterial load of the WT strain 6 h upon infection (Figure 4B) was associated with higher cytokine induction (Figure 4A). Moreover, the association found *in vivo* for cytokine production
and pronounced bacteremia (Figure 3) underlines the bacterial dose-dependency observed in vitro using either whole blood or PBMC.

To test if the results obtained using the cps2 strain 10 are representative of different S. suis serotypes, two further S. suis strains with clinical relevance, but different serotypes were included: the cps7 strain 13-00283-02 (104) and the cps9 strain 16085/3b (105). TNF-α was induced at similar levels by all three strains and increased dose-dependently up to 6 ng/ml (Figure 5B). IL-6 induction was highly donor-dependent and varied between 0 and 4 ng/ml in all three strains. The IL-10 induction was also dependent on the bacterial load between 0.1 and 1.8 ng/ml by all three strains. This shows that S. suis strains of different serotypes induce TNF-α, IL-6 and IL-10 similarly.

IL-10 is a potent anti-inflammatory mediator. To investigate a possible regulatory effect of S. suis-induced IL-10 on the production of the pro-inflammatory cytokines IL-6 or TNF-α, both cytokines were measured following S. suis stimulation of PBMC in the presence of a neutralizing anti-porcine IL-10 antibody. Compared to the control, IL-10 neutralization increased the levels of TNF-α and IL-6 (Figure 5C). Although the differences were not significant, a trend emerged comparing the PBMC of individual piglets in the absence and presence of neutralizing anti-IL-10 antibodies.

These findings suggest that S. suis-induced IL-10 might reduce the production of the pro-inflammatory cytokines IL-6 and TNF-α.

3.3. Encapsulated S. suis induces TNF-α in monocytes, but not in granulocytes

Cells of the innate immune system, such as monocytes, macrophages and neutrophils, have been shown to be producers of TNF-α, IL-6 and IL-10 upon stimulation with bacterial antigens in mice and humans (100, 114, 117, 118). To determine the contribution of myeloid cells of the blood to the production of the detected cytokines, porcine PBMC, CD14-positive monocytes isolated from the PBMC and granulocytes from the blood of pigs from the same herd were stimulated with WT S. suis strain 10 or with the acapsular mutant, and measured cytokines in the supernatants.

The purity of the CD14-positive fraction was assessed by flow cytometry. Since anti-CD14 antibodies did not perform sufficiently and did not allow to distinguish between CD14-negative and CD14-positive populations, the separation purity was instead assessed with the myeloid marker CD172a as a frequency of all CD3-negative cells (Figure 6A). The frequency of myeloid cells was enriched to >95% in the CD14-positive fraction, compared to ~5% of myeloid cells in the unseparated PBMC fraction (Figure 6B).
Granulocytes were isolated from the pellet after two density gradient centrifugations of whole blood. The purity of the granulocyte pellet was assessed microscopically after staining for eosinophilic and basophilic structures using a Diff Quik® staining kit by Medion Diagnostics AG, Düdingen, Switzerland. The granulocyte pellet contained >95% neutrophils (Figure 6C).

Figure 6 – Validation of separation purity of monocytes by flow cytometry and of granulocytes by microscopy.
(A) Flow cytometry gating for the quantification of CD172a-positive cells. (B) Plot of frequency of CD172a-positive cells as percentage of viable CD3-negative cells in unseparated PBMC and in the CD14-positive fraction after magnetic cell separation for all 11 donors. (C) Separation purity of granulocytes after density gradient centrifugation for all 3 donors. Representative cells from the granulocyte pellet were transferred to a glass slide and stained with the Diff Quik® staining kit (Medion Diagnostics AG, Düdingen, Switzerland). Cells were counted microscopically.

The blood leukocytes of pigs contain up to 50% granulocytes and 5 – 10% monocytes (119). In vitro cell numbers of PBMC, CD14-positive monocytes and granulocytes were chosen accordingly: PBMC – 1 x 10⁶ cells/well (200 µl), monocytes – 5 x 10⁴ cells/well, granulocytes – 1 x 10⁶ cells/well. For adequate comparison of PBMC, isolated monocytes and granulocytes, the same S. suis
Results

The PBMC fraction, containing lymphoid cells and monocytes, produced low amounts of TNF-α (median 0.3 ng/ml), IL-6 (median 0.1 ng/ml) and IL-10 (median 0.2 ng/ml) in response to WT S. suis, and high amounts (median of TNF-α: 14.5 ng/ml, IL-6: 1.0 ng/ml, IL-10: 1.7 ng/ml) in response to the acapsular mutant (Figure 7A). The monocyte fraction produced clearly detectable levels of TNF-α (median 0.7 ng/ml) after stimulation with the WT strain and high levels of TNF-α (median 4.0 ng/ml) with the acapsular strain. IL-6 and IL-10 were detectable in monocytes stimulated with the acapsular strain (median IL-6: 0.4 ng/ml, IL-10: 0.6 ng/ml), but not after stimulation with the WT strain. Neither IL-6 nor IL-10 were detectable in granulocytes when stimulated with the WT strain (Figure 7B). Stimulation with the acapsular strain induced TNF-α (max. 3.3 ng/ml, median 0.42 ng/ml) in granulocytes, but at lower levels than in stimulated monocytes, whereas IL-6 and IL-10 induction in granulocytes was detectable only at a very low level in some samples (Figure 7B).

In summary, it was demonstrated that monocytes are the main myeloid producers of TNF-α induced by encapsulated WT S. suis.

Figure 7 - Monocytes are the main producers of TNF-α in response to encapsulated S. suis. (A) Levels of TNF-α, IL-6 and IL-10 secreted by PBMC and CD14-positive monocytes after stimulation with the WT S. suis strain 10 (n = 4-
Results

7) or the acapsular mutant strain 10cpsΔEF for 42 h in the presence of antibiotics. PBMC were cultivated at 1 x 10^6 cells/well (200 µL) and monocytes were cultivated at 5 x 10^4 cells/well. Bacteria were always used at 1 x 10^6 cfu/well, which is equivalent to a PBMC-to-bacteria ratio of 1:1. Graphs show pooled data of four independent experiments with seven to 10-week-old piglets. Depending on the resulting cell yield of the monocyte separation, fractions were stimulated with S. suis strain 10 and/or 10cpsΔEF. (B) Density gradient-purified granulocytes (1 x 10^6 cells/well) from different donors, but pigs of the same herd (n = 11) were stimulated under the same conditions as the PBMC and the monocytes. The cytokines were quantified from cell culture supernatant by ELISA. Graphs show data from two independent experiments with seven to 10-week-old piglets. * p < 0.05; ** p < 0.01; *** p < 0.001 according to Mann Whitney test of control (medium) versus S. suis-stimulated samples.

3.4. **TNF-α induction is not crucial for bacterial killing of S. suis in vitro, not even in the absence of S. suis-specific immunoglobulin (Ig) G**

It was demonstrated that S. suis induces pro- and anti-inflammatory cytokines in vivo (Figure 3), in whole blood (Figure 4) as well as in PBMC and in isolated monocytes (Figure 5, Figure 7). The most prominent cytokine detected in the in vitro assays is TNF-α, since it is produced in high amounts in the whole-blood assay even by the encapsulated WT strain 10 (Figure 4). Whether S. suis-induced TNF-α is able to affect bacterial killing remains elusive.

TNF-α secretion was induced rapidly after bacterial contact (2 h, Figure 4A). To determine the time point of bacterial killing and TNF-α release more precisely, a kinetic analysis in whole blood was performed in 30 min intervals after in vitro infection with WT S. suis strain 10 (2 x 10^6 cfu/ml). TNF-α levels in plasma and bacterial survival factors were determined at these time points. TNF-α was induced only after 90 min of stimulation, but bacteria were already killed after 30 min (Figure 8A).
Results

Figure 8 - TNF-α does not contribute to bacterial killing in vitro, not even in the absence of S. suis-specific antibodies. (A) Kinetics of TNF-α induction and bacterial survival after infection of whole blood with 2 x 10^6 cfu/ml S. suis strain 10 (n = 3). (B) Blood samples of piglets with low specific IgG (n = 2–4) or blood cells reconstituted with colostrum-deprived serum (CDS, see Section 4.2 Methods) (no specific IgG; n = 3–5) were infected with the viable S. suis strain 10 alone or additionally treated with porcine recombinant TNF-α (rTNF-α, 10 ng/ml) or neutralizing anti-TNF-α antibody (4 µg/ml). Bacterial survival was determined after 2 h. (C) Relative units per mL (RU/ml) of S. suis strain 10-specific IgG in sera of different groups of piglets. RU were calculated relative to a reference serum. Blood and sera were categorized based on the amount of S. suis strain 10-specific IgG: IgG-high > 60/ml RU (n = 3); IgG-low < 60 RU/ml (n = 4); No IgG = 0 RU/ml, using CDS with no detectable S. suis strain 10-specific IgG antibodies for the reconstitution of porcine blood cells. Graphs show data of four independent experiments with six to eight-week-old piglets.
Detection of *S. suis* (strain 10)-specific IgG from plasma samples of the whole blood revealed a high antibody background (>60 relative units/ml, defined as "IgG-high", Figure 8C) in these blood samples. This suggests that TNF-α does not contribute to bacterial killing in this experimental setup, but that *S. suis*-specific antibodies are critical for the rapid killing. Therefore, whole blood samples with low *S. suis*-specific IgG (<60 RU/ml, defined as "IgG-low", Figure 8C) were chosen and, in a further approach, blood cells were reconstituted with colostrum-deprived serum (CDS, named “no IgG”) to completely exclude the interfering effects of antibody-mediated mechanisms on bacterial killing. To investigate the effects of TNF-α in more detail, recombinant TNF-α (rTNF-α, 10 ng/ml) or a neutralizing anti-TNF-α antibody were added to the *S. suis*-stimulated blood assay. In whole blood of the IgG-low group, the addition of rTNF-α did not increase bacterial killing (Figure 8B, left panel). To investigate the effect of endogenous TNF-α on killing, a neutralizing anti-TNF-α antibody was additionally used. The neutralization of endogenous TNF-α also did not change bacterial survival. In the approach with reconstituted porcine blood cells with CDS, *S. suis* induced TNF-α only marginally (Figure 8B, right panel). As expected, *S. suis* showed better survival in the CDS background compared to the IgG-low background. However, bacterial killing was not affected by the addition of rTNF-α.

In conclusion, under the chosen experimental conditions, TNF-α does not contribute to the killing of *S. suis* in blood, even not in the absence of specific antibodies.

**4. DISCUSSION**

*S. suis* is an important pathogen in the piglet farming industry. The pathogenesis of *S. suis* is linked to invasive infection resulting in septicemia, meningitis, arthritis, or endocarditis (46). Bacteremia as a potential mechanism for dissemination of this pathogen goes along with the manifold clinical symptoms. Whether bacteremia provokes the release of cytokines in the natural host of *S. suis* was the focus of this study by an experimentally induced invasive infection.

An induction of IL-6 and the anti-inflammatory mediator IL-10 could be detected after 13 – 19 hpi in serum of intravenously *S. suis*-infected piglets that showed a pronounced bacteremia. By *in vitro* stimulation with *S. suis*, the *in vivo* results were confirmed showing that *S. suis* induces TNF-α and IL-6 following *in vitro* stimulation of porcine blood. Similar to the *in vivo* data, increased cytokine production accompanied the growth of *S. suis* in the whole-blood assay and in PBMC stimulated with higher doses of bacteria. Thus, the data demonstrate that increased bacterial load with *S. suis* in the blood leads to increased cytokine production. This shows the relevance of the whole-blood assay as an *in vitro* system and confirms earlier findings (101) using a porcine whole-blood assay to mimic some aspects of bacteremia. Furthermore, the presented study demonstrates the survival and growth of *S. suis* in blood despite the presence of pro-inflammatory cytokines IL-6.
and TNF-α. Therefore, these pro-inflammatory cytokines do not appear to be crucial for killing mechanisms. Specifically, TNF-α did not play a role in bacterial killing in whole blood in vitro when recombinant TNF-α or a neutralizing antibody against TNF-α were added, not even in conditions with low *S. suis*-specific antibodies. In addition, it was shown that the induction of IL-10 limits the production of the pro-inflammatory cytokines TNF-α and IL-6.

4.1. **Effects of cytokine induction by *S. suis* in blood**

**Cytokine kinetics**

The induced cytokines detected in this study (Figure 3, Figure 4) match the pro-inflammatory cytokine profile described in the *in vitro* study in porcine blood by Segura et al. (101). In addition, the cytokine levels by stimulation with different *S. suis* serotypes are comparable (Figure 5B) (101). The differences found in the onset and magnitude of cytokine production *in vitro* may be related to genetic differences between the pig breeds and differences in procedures of *in vitro* experiments. The sequential onset of cytokine production, starting with TNF-α and followed by IL-6 and IL-10, has also been found in other studies (101, 95, 120, 121). A systemic infection of mice with an intraperitoneally administered suilysin-positive virulent serotype 2 strain led to a detectable TNF-α increase in serum between 3 and 6 hpi, but to a decline at 6 hpi, similar to TNF-α levels before infection (115). Due to experimental restrictions by the animal permit for the *in vivo* infection experiment (Figure 3), serum cytokine levels between 1 and 13 h post infection could not be analyzed in the presented study. Therefore, it is possible that a putative early peak of TNF-α (1 to 13 h) has been missed.

**Impact of bacterial capsule on cytokine induction**

In the whole-blood assay, the acapsular strain induced cytokines at a high magnitude although it was killed rapidly, while the WT strain induced comparable cytokine levels, but was not killed (Figure 4). The WT strain can evade killing through its bacterial capsule, which has been shown to effectively inhibit phagocytosis (81–83, 85). The higher proliferation of the WT strain results in an increased and prolonged exposure of immune cells to bacterial antigens. However, the capsule does not only mask surface-associated bacterial antigens, but exposed cell wall components are also more potent cytokine inducers than the capsule (101, 95). Previous studies in whole blood and human cell culture have demonstrated that cell wall components of *S. suis* can induce TNF-α and IL-6, depending on the CD14 receptor (100) and on toll-like receptor (TLR) 2 (95). Therefore, the acapsular strain induces cytokines at a higher magnitude (101, 95).

**Effects of induced cytokines on bacteremia**

The current understanding is that killing of *S. suis* is dependent on phagocytosis (75) and mediated by opsonizing antibodies. Segura *et al.* showed that opsonization of the *S. suis* serotype 2 with
specific immune serum reduced induction of the pro-inflammatory cytokines TNF-α, IL-1β and IL-6, associated with decreased bacterial survival \((101)\). The observed \textit{in vivo} induction of IL-6 and IL-10 in bacteremic pigs (Figure 3) raises the question of whether the induction of pro-inflammatory cytokines also has protective properties in bacteremia. However, it has been shown that decreasing IL-6 levels are associated with a protective effect in pneumococcal septicemia in pigs \((122)\). Furthermore, a co-infection study in porcine bone marrow-derived dendritic cells (BMDC) experimentally infected with porcine reproductive and respiratory syndrome virus (PRRSV) and secondary infection with \textit{S. suis} showed that phagocytosis of bacteria was impaired when IL-6 and TNF-α were upregulated \((102)\), pointing to a detrimental effect of IL-6 or TNF-α upregulation. This is in line with earlier studies demonstrating a detrimental effect of pro-inflammatory cytokines during systemic inflammatory conditions, like bacteremia, sepsis or septic shock \((91, 92, 123, 124)\). Therefore, the induction of IL-10 by \textit{S. suis} and the observed limiting effect of IL-10 on TNF-α and IL-6 secretion (Figure 5C) can be interpreted as a physiological negative feedback to counteract an uncontrolled pro-inflammatory immune response and to ultimately allow for reversion to a state of immunological equilibrium. However, this feedback can have detrimental effects, too.

The infection of mice with influenza virus has been shown to trigger increased IL-10 levels in convalescent animals, but ultimately resulted in an increased susceptibility to \textit{S. pneumoniae} infection and a lethality of 100\% \((125)\). Since it has been shown that porcine PBMC also highly upregulate IL-10 after PRRSV infection \((126)\), a similar scenario could be possible in the field in pigs infected with PRRSV and a secondary invasive \textit{S. suis} infection. The detrimental effects of high IL-10 induction have been further demonstrated for \textit{Klebsiella pneumoniae} \((127)\) and meningococcal infection \((128)\), and could result in reduced phagocytic and bactericidal activity in neutrophils \((129)\).

The presented data demonstrate that a potential negative impact of IL-10 on \textit{S. suis} killing by downregulation of TNF-α is unlikely, since TNF-α was not involved in bacterial killing \textit{in vitro}. Since TNF-α is also known as an inducer of oxidative burst in neutrophils, \textit{in vivo} this cytokine could be able to support antibody-mediated killing mechanisms against streptococci, which are catalase-negative and therefore sensitive to reactive oxygen species \((130)\). On the other hand, TNF-α has long been known to also have negative effects on the outcome of which has also been demonstrated by several studies investigating TNF-α neutralization as a treatment against septic shock and bacteremia \((131–133)\). Therefore, TNF-α may contribute to an inflammatory response detrimental to the porcine host. However, in a pig model of \textit{S. pneumoniae} sepsis, it was directly demonstrated that neutralization of TNF-α has no protective anti-inflammatory effect \((134)\).
Individual differences in cytokine production

The magnitude of cytokine responses to *S. suis* infection varied notably between individuals, *in vivo* (Figure 3) and *in vitro* (Figure 5, Figure 7). In humans, single nucleotide polymorphisms (SNP), in the TNF-α, CD14, or TLR genes have been shown to have a considerable impact on the outcome of sepsis (135, 136, 60). It is possible that pigs with high levels of cytokines have polymorphisms which make them especially prone to overshooting inflammation. Furthermore, inflammation and coagulation are associated and can amplify each other, so an individual’s tendency for coagulation could be associated with the outcome of sepsis (137–139).

In summary, a high bacterial antigen load seems to be associated with the induction of IL-6 and TNF-α, and could cause an inflammatory cascade during bacteremia, potentially contributing to a detrimental outcome of invasive *S. suis* infection, especially since TNF-α did not contribute to bacterial killing in whole blood *in vitro*. For a more detailed understanding of the role of cytokines during an invasive infection in pigs, histopathological scoring could be of advantage to investigate the local detrimental effects induced by pro-inflammatory cytokines.

4.2. Cellular sources of induced cytokines

Monocytes separated from PBMC with magnetic anti-human CD14 beads were identified as the main producers of TNF-α by comparing cytokine levels released by PBMC and isolated monocytes after the addition of *S. suis* (Figure 7). Monocytes possess numerous pattern recognition receptors and could be more reactive to *S. suis* due to a previously described extracellular binding of *S. suis* to monocytes in the blood stream, which is independent of phagocytosis (82, 72). This bacterial attachment to phagocytic cells without internalization was also demonstrated for the murine macrophage cell line J774 (73) and release of pro-inflammatory cytokines like IL-6 and TNF-α by human monocytes in response to *S. suis* has previously been demonstrated using the human monocyte cell line THP-1 (100).

Monocytes in humans can be divided based on their expression of the LPS co-receptor, also known as CD14, and the Fcγ receptor III (FcγRIII), also known as CD16 (Table 5): CD14++ CD16− classical monocytes, CD14++ CD16+ intermediate monocytes, and CD14+ CD16++ non-classical monocytes (140–142), the latter two subsets sometimes simply being referred to as CD16+ monocytes. It is suspected that that those three subsets represent transitional stages during an immune response (143, 144). In pigs, a CD14low CD163high population of monocytes has been deemed equivalent to the intermediate population in humans based on transcriptional profiling (145).
Porcine monocytes respond to bacterial antigens in a similar way to human and murine monocytes by detecting PAMPs in a TLR-dependent manner and upregulating pro- and anti-inflammatory cytokines, including IL-1β, IL-6, TNF-α, IL-12p70, and IL-10 (95, 118). Therefore, the detected TNF-α production and the absence of IL-6 production (Figure 7) suggest that the isolated monocytes studied above are most similar to the non-classical/intermediate fraction in humans.

However, cytokine induction in vivo is probably a far more complex process requiring cell types that are missing in the in vitro model. For example, and there is evidence suggesting that endothelial cells (EC) can integrate and relay pro-inflammatory cytokine signaling, possibly by interaction with monocytes (146, 147). According to Chimen et al., nonclassical/intermediate monocytes may secrete high levels of TNF-α in proximity of endothelial cells (EC), which in turn upregulate pro-inflammatory genes and also E-selectin (146) facilitating neutrophil recruitment. To counteract this pro-inflammatory response, classical monocytes then secrete IL-6, which in this context has anti-inflammatory effects by overriding the activating effects of TNF-α, reducing E-selectin expression in EC through SOCS3 and ultimately reducing neutrophil recruitment. Furthermore, a study on functional reprogramming of monocytes during sepsis showed that monocytes secrete high levels of cytokines like IL-6 and IL-10 during sepsis and transition to a more immunosuppressive state during recovery of the same patients, which points to the importance of “regulatory” IL-6 and IL-10 induction during sepsis and a controlled return to a non-inflammatory state for host survival. Sepsis and mortality in invasive S. suis infection in pigs may therefore result from an imbalance of the activities of those monocyte subsets, possibly through an overshooting pro-inflammatory cascade (bias towards nonclassical/intermediate

---

**Table 5 – Overview of blood monocyte nomenclature in humans, mice and pigs.** Table modified after Ziegler-Heitbrock et al., 2010 (140).

1 according to the Nomenclature Committee of the International Union of Immunologic Societies (140).
2 according to Fairbairn et al., 2013 (145)
3 according to Chimen et al., 2017 (146)
Discussion

monocytes, TNF-α^{high}), while recovering pigs also have a controlled inflammatory TNF-α response from nonclassical monocytes, but manage to control the inflammation through induction of IL-10 and a multi-factorial "regulatory" effect IL-6.

IL-10 was not produced by monocytes or granulocytes but to varying amounts (0.25 – 2 µg/ml) by PBMC when stimulated with the encapsulated or the acapsular strain (Figure 5). Müller-Alouf et al. (148) demonstrated that human PBMC produce 0.5 to 1.5 ng/ml of IL-10 when stimulated with heat-killed group A streptococci for 48 hours. Furthermore, IL-10 production was increased substantially by stimulation with the superantigen exotoxin A, demonstrating that IL-10 is produced in a strongly lymphocyte-dependent manner. This is in line with the presented data showing moderate amounts of IL-10 only in the PBMC fraction.

Furthermore, in the presented study TNF-α production was strongly reduced by the reconstitution of blood with CDS as compared with sera containing high and low levels of S. suis-specific IgG (Figure 8), which suggests that opsonization by antibodies is important for TNF-α production, possibly for phagocytosis by granulocytes. Since phagocytosis of S. suis is impaired by the polysaccharide capsule (82) and granulocytes only secreted TNF-α in vitro when stimulated with the acapsular mutant (Figure 7), it is plausible that cytokine induction in granulocytes is dependent on phagocytosis. Furthermore, IL-6 induction in sepsis of mice seems to be neutrophil-and complement-dependent, since expression of the receptor for the complement protein C5a (C5aR) is required for induction of IL-6 (149). This hints to another layer of cellular interaction influencing the outcome of sepsis, possibly related to IL-6 induction in monocytes and their role in neutrophil recruitment.

In summary, it is plausible that monocytes and granulocytes release cytokines in a co-dependent manner to orchestrate the adaptive immune response to S. suis. The individual contributions of monocytes and granulocytes to the porcine cytokine response could be further elucidated by more elaborate cell separations and analyses, including transcriptional profiling, extensive surface marker analysis, and possibly by comparing monocytes from different stages of an acute S. suis infection.

4.3. Outlook

Since the uncontrolled induction of pro-inflammatory mediators like TNF-α or IL-6 seems to be associated with a detrimental outcome of invasive porcine S. suis infection, the regulation of those cytokines could be a potential target to treat S. suis infections.

The cell culture systems described here can be used in the future to investigate the relationship between S. suis infection and dysregulation of pro-inflammatory cytokines more closely. This system can not only be used to investigate the cytokine response and the cellular sources of the
dysregulated cytokines in more detail, but also to expand the system by comparing with cell culture systems using primary cells of secondary lymphoid organs, like lymph nodes and tonsil.

Other possibilities would be to investigate a possible relationship between the levels of *S. suis*-specific antibodies and pro-inflammatory cytokines, or an interaction between activated pro-inflammatory cells of the innate immune system and a corresponding immune response by lymphoid cells.
5. SUMMARY

*Streptococcus suis* is a common commensal in pigs and colonizes the mucosa and secondary lymphoid organs in healthy individuals. Invasive infections occur regularly in young weaning piglets (7-10 weeks of age), which cannot be fully explained by the immunological gap, a phase of deficiency in adaptive humoral immunity, or by highly virulent strains. Since virulent strains colonize the entire herd and the immunological gap occurs in all piglets at the same time, it is not clear why only some individuals are prone to *S. suis*-induced disease. *S. suis* first enters the blood (causing bacteremia) and subsequently spreads to peripheral organs, like brain, heart or joints (causing septic shock, meningitis, myocarditis or arthritis), which can be fatal. The transition from the colonizing state at the mucosa to invasive state in peripheral organs therefore has a key role in pathogenesis, but is still poorly understood. Since the systemic spread of *S. suis* occurs via the blood, the blood represents a critical stage before the bacteria can infect organs. It is incompletely understood why in some individuals, *S. suis* leads to controlled bacteremia, and in others the bacteremia evolves into an uncontrolled septicemia (or into septic/toxic shock). In humans, septicemia is defined as uncontrolled bacterial infection which is accompanied by a systemic inflammation, usually caused by bacterial surface components or secreted toxins. This systemic inflammatory reaction is caused by pro-inflammatory cytokines which are secreted by cells of the innate and adaptive immune system, and can amplify each other. It is questionable whether pathogenesis in septicemic pigs is comparable to *S. suis*-induced septic/toxic shock in humans. A number of infection studies in human cell lines and porcine whole blood demonstrated that the bacterial capsule inhibits phagocytosis efficiently, while immunomodulatory effects are mainly mediated by the bacterial cell wall. However, it remained unclear, if the situation in vivo in pigs is comparable. The aim of this study was to establish an *in vitro* system of primary porcine cells and to compare it to the cytokine response in pigs in an *in vivo* infection.

Some of the investigated infected pigs, which had a pronounced bacteremia 13 hours after infection, showed elevated levels of the pro-inflammatory cytokine IL-6 after 13 hours and also increased levels of the anti-inflammatory cytokine IL-10 after 16 hours of infection. However, the pro-inflammatory cytokines TNF-α, IFN-γ, or IL-17A were not elevated at these time points. TNF-α is typically induced early after an infection and was possibly already downregulated at the time of the earliest sampling (13 hours after infection). These pigs with a pronounced bacteremia showed a typical pro-inflammatory cytokine response, which is counteracted by anti-inflammatory cytokines at the end. On the other hand, pigs with controlled bacteremia did not develop blood levels of IL-6 and IL-10. In the subsequent analysis looking at *S. suis*-infected whole blood it was shown that the encapsulated wild type strain 10 already induced elevated TNF-α, IL-6 and IL-10 levels after 2 hours, but was not killed. The isogenic acapsular deletion mutant strain 10cpsΔEF induced a similar increase of cytokines at a comparable kinetic, but was killed
effectively. Furthermore, *in vitro*-infected peripheral blood mononuclear cells (PBMC) showed a higher production of TNF-α, IL-6 and even IL-10 when infected with acapsular *S. suis* compared to encapsulated wild type *S. suis*. Also, the cytokine levels were associated with the amount of *S. suis* present. Taken together, this allows the conclusion that encapsulated strains, which survive better, induce cytokines in lower amounts over a longer time. Conversely, acapsular strains seem to induce stronger cytokine responses, but are killed faster. Strains with different capsule compositions (*cps2, cps7, cps9*) showed no differences in cytokine induction indicating serotype-independent cytokine regulation. Additionally, it was shown that inhibition of endogenous IL-10 via a neutralizing antibody was able to limit release of TNF-α and IL-6. This confirms the previously mentioned feedback loop of anti-inflammatory cytokines regulating the pro-inflammatory response. For the understanding of dysregulated systemic cytokine secretion, the identification of the cellular sources of the secreted cytokines is essential. Therefore, monocytes and granulocytes were isolated from porcine PBMC and stimulated separately with *S. suis*. It could be shown that encapsulated *S. suis* induces TNF-α production mainly by monocytes, but not by granulocytes. The cellular sources of IL-6 and IL-10 could not be clearly identified. TNF-α is typically produced by monocytes and macrophages as a fast pro-inflammatory response upon infection and therefore it plays a crucial role in the development of sepsis. In this study it could be shown that TNF-α was released fast and in large amounts by monocytes. Therefore, the final question was whether TNF-α has a bactericidal effect during infection of porcine whole blood *in vitro*. Since antibodies in blood play an essential role in the killing of *S. suis*, the bactericidal effect of TNF-α was investigated in presence of high, low and especially in absence of *S. suis*-specific IgG. In presence of high *S. suis*-specific IgG, *S. suis* strain 10 was effectively killed, as expected. In the presence of low *S. suis*-specific IgG, recombinant TNF-α was also added or alternatively inhibited by a neutralizing antibody. Both treatments had no effect on the killing of *S. suis*. Even in the absence of *S. suis*-specific IgG, TNF-α did not affect bacterial survival. This suggests that TNF-α does not contribute to bacterial killing (even not in the complete absence of antibodies) in this experimental *in vitro* system, but that *S. suis*-specific antibodies are critical for rapid bacterial killing.

In summary, it could be shown that the pro- and anti-inflammatory cytokine induction in the *in vitro* whole blood model is comparable to the *in vivo* situation. The presence, but not the composition, of the bacterial capsule has a limiting impact on the cytokine induction, and also reduces the killing of bacteria, as shown previously. Monocytes could be identified as the main producers of TNF-α in porcine blood. Therefore, the *in vitro* model has contributed to the understanding of the induction of pro- and anti-inflammatory cytokines during *S. suis* infection of the blood. This model offers a basis for further investigation of the interaction and of the cellular sources of cytokines during infection of the blood by *S. suis*. 

39
6. ZUSAMMENFASSUNG


In einigen der *in vivo*-infizierten Schweine, die 13 Stunden nach Infektion mit *S. suis* Stamm 10 eine ausgeprägte Bakteriämie zeigten, waren nach 13 Stunden bereits das pro-inflammatorische Zytokin IL-6 sowie nach 16 Stunden das anti-inflammatorische Zytokin IL-10 erhöht, nicht jedoch die pro-inflammatorischen Zytokine TNF-α, IFN-γ oder IL-17A. TNF-α ist typischerweise sehr früh nach einer Infektion induziert und war zum Zeitpunkt der frühesten Probennahme (13 h nach Infektion) möglicherweise wieder abgeklungen. Dieses Bild entspricht einer typischen pro-
Zusammenfassung

... inflammatorischen Zytokinantwort, in deren Anschluss anti-inflammatorische Zytokine produziert werden, um die Entzündung auszubalancieren. Diejenigen Schweine, die eine Bakteriämie kontrollieren konnten, zeigten auch keine erhöhten Mengen an IL-6 oder IL-10. In einer weiteren Analyse mit *S. suis*-infiziertem Vollblut zeigte sich, dass der bekapselte Wildtypstamm 10 nach 2 Stunden bereits erhöht TNF-α, IL-6 sowie IL-10 induzierte, jedoch nicht abgetötet wurde. Die unbekapselte Deletionsmutante 10cpsΔEF induzierte dieselben Zytokine in einer vergleichbaren Kinetik, wurde jedoch erwartungsgemäß abgetötet. Weiterhin zeigten *in vitro* infizierte mononukleäre Zellen des peripheren Bluts (PBMCs) bei Infektion mit unbekapseltem *S. suis* eine höhere Produktion von TNF-α und IL-6 aber auch von IL-10 im Vergleich zu bekapseltem Wildtyp. Darüber hinaus war die Zytokinmenge abhängig von der *S. suis*-Infektionsdosis. Zusammengenommen lässt dies darauf schließen, dass die besser überlebenden bekapselten Stämme Zytokine in geringerem Menge, aber dafür über einen längeren Zeitraum induzieren. Umgekehrt scheinen unbekapselte Stämme Zytokine stärker zu induzieren, aber auch schneller abgetötet zu werden. Stämme mit verschiedenen Kapselgenen (*cps2, cps7, cps9*) zeigten jedoch keine Unterschiede in der Zytokininduktion, was auf eine Serotyp-unabhängige Zytokinregulation hinweist. Darüber hinaus konnte in Zellkultur von PBMCs gezeigt werden, dass die Neutralisation von endogenem IL-10 die Induktion von TNF-α und IL-6 limitiert, was wieder die zuvor gezeigte Selbstregulation der freigesetzten pro-inflammatorischen Zytokine in den infizierten Schweinen *in vivo* bestätigt. Zum Verständnis einer dysregulierten Zytokinausschüttung ist die Identifizierung der Zytokin-produzierenden Zellen entscheidend. Deshalb wurden Monozyten und Granulozyten aus PBMCs des Schweins isoliert und separat mit *S. suis* infiziert. Dabei konnte bestätigt werden, dass bekapselte *S. suis* TNF-α hauptsächlich von Monozyten produziert wird, nicht von Granulozyten. Für IL-6 und IL-10 konnten die Produzenten nicht eindeutig zugeordnet werden. TNF-α wird typischerweise von Monozyten und Makrophagen als schnelle pro-inflammatorische Reaktion auf Infektionen freigesetzt und spielt eine entscheidende Rolle in der Entwicklung einer Sepsis. Auch in den Untersuchungen dieser Arbeit konnte gezeigt werden, dass TNF-α nach Infektion mit *S. suis* schnell und in großen Mengen von Monozyten freigesetzt wird. Daher sollte schließlich *in vitro* in porzinem Vollblut untersucht werden, ob TNF-α eine bakterizide Wirkung hat. Da im Blut Antikörper eine entscheidende Rolle bei der Abtötung von *S. suis* spielen, wurde der bakterizide Effekt von TNF-α in Gegenwart von unterschiedlich hohen Spiegeln und besonders in Abwesenheit von *S. suis*-spezifischem IgG untersucht. In Gegenwart eines hohen IgG-Spiegels wurde *S. suis* wie erwartet effektiv abgetötet. In Gegenwart von niedrigem IgG-Spiegel und in Abwesenheit von IgG wurde rekombinantes TNF-α zusätzlich zugegeben bzw. durch einen neutralisierenden Antikörper blockiert. Beide Behandlungen hatten keinerlei Einfluss auf das Abtöten der Bakterien. Dies deutet darauf hin, dass TNF-α in diesem *in vitro*-System nicht zum Abtöten der Bakterien beiträgt (auch nicht in...
Abwesenheit von Antikörpern), sondern S. suis-spezifische Antikörper entscheidend für eine schnelle bakterielle Abtötung sind.

7. REFERENCES


2. Chanter, N. Streptococci and enterococci as animal pathogens. *J Appl Microbiol* 1997, 83 (S1), 100S-109S.


47. Amass, S. F.; Clark, L. K.; Wu, C. C. Source and timing of *Streptococcus suis* infection in neonatal pigs: implications for early weaning procedures.


73. Segura, M.; Gottschalk, M. *Streptococcus suis* interactions with the murine macrophage cell line J774: adhesion and cytotoxicity. *Infection and immunity* 2002, 70 (8), 4312–4322.


105. Rieckmann, K.; Seydel, A.; Klose, K.; Alber, G.; Baums, C. G.; Schütze, N. Vaccination with the immunoglobulin M-degrading enzyme of *Streptococcus suis*, Ide, leads to protection against a highly virulent serotype 9 strain. *Vaccine: X* 2019, 100046.


8. ACKNOWLEDGMENT

This work would not have been possible without the help of many people who have contributed directly or indirectly to my dissertation, some of which would otherwise go uncredited.

I would like to thank Leipzig University for awarding me a Doktorandenförderplatz to carry out my PhD thesis. Thanks to Prof. Dr. Thomas Magin at the Faculty of Life Sciences for the supervision of my thesis and for the assessment of this thesis. Thanks to Prof. Dr. Peter Valentin-Weigand for the second assessment of this thesis. Special thanks to Prof. Dr. Gottfried Alber for giving me the opportunity to work on this PhD project, for his supervision and for his scientific advice. Special thanks to Dr. Nicole Schütze for unconditional scientific, conceptual, analytical and experimental supervision and support throughout my entire PhD time.

I would like to thank the Institute of Bacteriology and Mycology at the Faculty of Veterinary Medicine. Firstly Prof. Dr. Christoph G. Baums for the establishment of the S. suis project at the faculty and the opportunities for collaboration he provided; furthermore all members of the Institute for their essential help with sample acquisition of porcine blood and support regarding bacterial samples and analyses: Dr. Renée Bergmann, Sophie Kähl, Ann-Kathrin Krieger, Carolin Liedel, Léonie Mayer, Sophie Öhlmann, Dr. Karoline Rieckmann, Dr. Viktoria Rungelrath, Dr. Anna Seydel, Christine Weiße.

Thanks to Lutz Gumpert for his essential help during sample acquisition, and thanks to the porcine donors who have bled for this work.

Many thanks to the people who have been with me at the Institute of Immunology at the Faculty of Veterinary Medicine, and who have been a great help scientifically, technically or emotionally: Prof. Dr. Dr. Mathias Büttner, Dr. Maria Eschke, Elisabeth Greßler, Anett Grohs, Dr. Laura Heyen, Dr. Mahmod Muhsen, PD Dr. Uwe Müller, Dr. Martina Protschka, Dr. Friederike Rabiger, Dr. Sabine Siegemund.

Special thanks to Dr. Laura Schneider, long-time colleague and good friend, for always lending an ear and offering honest opinions, and special thanks to Silke Lehnert for providing excellent technical assistance.

Although there are no appropriate words to express my gratitude, I want to thank my parents, my grandparents and my sister for always supporting me and for being the biggest emotional support I could wish for.

Finally, I want to thank Dr. Janine Starzonek, who has been and continues to be an incredibly strong foundation in my life in good and in bad times.
9. SELBSTSTÄNDIGKEITSERKLÄRUNG


Leipzig, ____________________

______________________________

Florian Hohnstein
10. WISSENSCHAFTLICHER WERDEGANG

Personal Data
Name: Florian S. Hohnstein
Nationality: German
Email: fs.hohnstein@gmail.com

School and Academic Education
04/2016 – present
PhD student at the Institute of Immunology, Faculty of Veterinary Medicine, Universität Leipzig
- PhD thesis: „Analysis of porcine cytokine response upon Streptococcus suis infection in vivo, in whole blood and in cell culture“

10/2013 – 12/2015
Master of Science in Molecular Cell Biology & Immunology, University of Tübingen

10/2010 – 09/2013
Bachelor of Science in Biology, University of Tübingen
- Bachelor thesis: „The role of the Guanine nucleotide exchange factor C3G during ventral furrow formation in Drosophila melanogaster“

08/2001 - 06/2009
Abitur, Neue Nikolaischule, Leipzig

Working experience and Methods
04/2016 – 09/2019
Research associate at the Institute of Immunology, Faculty of Veterinary Medicine, University of Leipzig
- Methods: Flow cytometry, primary cell culture, ELISA, bacterial isolation

04/2015 – 09/2015
Research assistant at the Institute of Immunology, University of Tübingen
• Methods: virus culture, virus titration, bacterial transformation, cell transfection, molecular cloning, genetic engineering (CRISPR/Cas9), primary cell culture of dendritic cells and T cells, culture of Vero cells, flow cytometry

12/2014
Student assistant at the Institute of Cell Biology, Department of Animal Genetics, University of Tübingen

• Methods: DNA isolation, PCR, cross-breeding genetics, confocal laser scanning microscopy, live imaging, digital image processing, *in silico* analysis of protein homology, practical fly work

11/2011 – 03/2013
Student assistant at the Department of Molecular Biology, Max Planck Institute for Developmental Biology

• Methods: DNA isolation, PCR, bacterial transformation, practical plant work

**Qualifications**

03/2015
Nachweis von Kenntnissen und Fähigkeiten gemäß Anlage 1 Abschnitt 1 bis 3 TierSchVersV (officially approved)

Leipzig, ___________.

______________________________
Florian Hohnstein
11. PUBLIKATIONSLISTE

Parts of this work were published in a peer-reviewed scientific journal:

1. **Hohnstein FS, Meurer M, de Buhr N, von Köckritz-Blickwede M, Baums CG, Alber G, Schütze N**, “Analysis of Porcine Pro- and Anti-Inflammatory Cytokine Induction by *S. suis In Vivo and In Vitro*, Pathogens 2020, 9, 40; doi:10.3390/pathogens9010040. Chosen as cover story for this Special Issue on *Streptococcus suis*.

**Posters**

2. Schütze N, **Hohnstein FS, Rungelrath V, Büttner M, Baums CG, Alber G**, “Innate TNF-α and IFN-γ production induced by *Streptococcus suis* in porcine PBMC is dependent on monocyte activation”, 6th European Veterinary Immunology Workshop (2018), Utrecht, Netherlands.


8. **Hohnstein FS, Baums CG, Alber G, Schütze N**, Analysis of functional T-cell subsets in porcine blood and secondary lymphoid organs with a potential role in immunity against *Streptococcus suis* infection”, Annual meeting of the AK veterinary immunology of the DGfI (2017), Bern, Switzerland.


10. **Hohnstein FS, Baums CG, Alber G, Schütze N**, “Analysing cell-mediated immunity in pigs upon infection with *Streptococcus suis*, 8th Autumn School of the German Society for Immunology e.V. (DGfI) (2016), Merseburg, Germany.
Presentations

11. **Hohnstein FS**, “*In vitro* analysis of the *Streptococcus suis*-induced cytokines in porcine PBMCs”, Mini symposium “Infection and Immune defense” (2019), Rothenfels, Germany.
